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ABSTRACT 
 
Bisphosphonates have been shown to be an effective method to treat detrimental 
bone loss that is associated with osteoporosis. In microgravity, astronauts experience 
mechanical unloading of the skeleton. This can cause detrimental bone loss. 
Bisphosphonates offer astronauts a pharmacological method to combat the negative 
effect of space flight. This study looked at the effectiveness of two bisphosphonate drug 
treatments administered prior to hindlimb unloading (HU) and their effect as a 
countermeasure to disuse induced bone loss and recovery following reambulation.  
The model used to mimic space flight was the adult HU rat model, specifically 6-
month old, male, Sprague-Dawley rats. The rats underwent 28 days of pre-treatment, 28 
days of HU and 56 days of recovery. The rats were divided into four treatment groups. 
The groups included an age-matched control group (AC) that did not undergo HU. The 
other groups that underwent HU were hindlimb unloaded control (HUC), alendronate 
pre-treated (ALN), and risedronate pre-treated (RIS). The effects of pre-treatment and 
the differences between the two drugs were explored. Data were collected ex vivo from 
left tibia using peripheral Quantitative Computed Tomography (pQCT) and mechanical 
testing at both the proximal metaphysis and the mid-diaphysis.  
The results of this study showed that bisphosphonates were able to prevent the bone 
loss that was seen in the HUC animals, and maintain bone at levels that were not 
statistically different from AC. Metaphysis pQCT scans showed that the drugs were able 
to significantly combat losses due to HU and were specifically effective in the 
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cancellous bone. Reduced platen compression tests showed that ALN and RIS were able 
to maintain cancellous strength in the metaphysis. Mid-diaphysis pQCT scans and 3-
point bend tests showed no significant changes in cortical bone due to the drug 
treatments or HU. Over recovery there were no indications that bisphosphonate pre-
treated animals fared worse than AC, despite the fact that they did not completely 
recover all lost bone. They also did not exhibit age related decline in cancellous bone. 
The drug pre-treatments did not show any significant differences when compared to each 
other. 
 
  
iii 
 
  
ACKNOWLEDGEMENTS 
 
As with any project as large as this there are plenty of people to thank for their 
contributions to this work. First, I would like to thank Dr. Tai for taking the time to serve 
on my thesis committee. I would like to thank Dr. Hogan, my committee chair, for his 
support of my work in this project, both in providing my funding and his intellectual 
contributions to the study. He has helped me to grow as both a person and a student and I 
thank him for that. I would additionally like to thank Dr. Bloomfield for both her 
participation as a member of my thesis committee and as a collaborator on this research 
project. The funding for this study was through NASA grant #NNX13AM43G.  
I would personally like to thank each and every member of the Bone Biomechanics 
Lab and the Bone Biology Lab. Countless hours of work have been put in by both 
graduate and undergraduate students in animal care, data collection, and data analysis. 
This thesis project could not be completed without this help.  
  
iv 
 
  
TABLE OF CONTENTS 
 
  Page 
ABSTRACT .................................................................................................................ii 
ACKNOWLEDGEMENTS ........................................................................................ iv 
TABLE OF CONTENTS ............................................................................................. v 
LIST OF FIGURES .................................................................................................. VII 
LIST OF TABLES ...................................................................................................... ix 
1. INTRODUCTION .............................................................................................. 1 
2. OBJECTIVES .................................................................................................... 6 
3. BACKGROUND ................................................................................................ 7 
3.1. The Basics of Bone Biology ........................................................................... 7 
3.2. Understanding Mechanical Testing Data ..................................................... 12 
3.3. The Effect of Bisphosphonates on Bone Biology ........................................ 14 
4. EXPERIMENTAL METHODS ....................................................................... 18 
4.1. Animal Study Background ........................................................................... 18 
4.2. Experimental Design .................................................................................... 21 
4.3. Ex Vivo Peripheral Quantitative Computed Tomography of Tibia ............. 25 
4.4. Ex Vivo 3-Point Bend Test of Tibia ............................................................. 29 
4.5. Ex Vivo Reduced Platen Compression Test of Proximal Tibia 
Metaphysis .................................................................................................... 31 
4.6. Statistical Analysis ....................................................................................... 34 
5. RESULTS......................................................................................................... 35 
5.1. Ex Vivo pQCT of the Left Tibia .................................................................. 36 
5.2. Ex Vivo 3-Point Bend Test of the Left Tibia ............................................... 63 
5.3. Ex Vivo Reduced Platen Compression Test of the Left Tibia ..................... 74 
6. DISCUSSION .................................................................................................. 82 
6.1. Comparison of pQCT Results ...................................................................... 82 
6.2. Comparison of 3-Point Bend Results ........................................................... 89 
v 
 
  
  Page 
6.3. Comparison of RPC Results ......................................................................... 91 
6.4. Overall Conclusions ..................................................................................... 92 
7. LIMITATIONS ................................................................................................ 94 
8. FUTURE WORK ............................................................................................. 95 
9. CONCLUSIONS .............................................................................................. 96 
REFERENCES ........................................................................................................... 98 
APPENDIX A. STATISTICAL ANALYSIS .......................................................... 105 
APPENDIX B. ADDITIONAL FIGURES .............................................................. 112 
  
vi 
 
  
LIST OF FIGURES 
 
  Page 
Figure 1. Sketch of Important Features of Long Bone. ...................................................... 8 
Figure 2. Diagram of Cortical and Cancellous Regions of Bone. ...................................... 9 
Figure 3. Osteoclasts and Osteoblasts in the Bone Remodeling Cycle. ........................... 11 
Figure 4. Graphical Representation of Extrinsic Force-Displacement Data with 
Important Data Markers. ................................................................................... 13 
Figure 5. Bisphosphonates and the Remodeling Cycle. ................................................... 15 
Figure 6. Diagram of Human and Rat Proximal Femur. .................................................. 21 
Figure 7. Rat Hindlimb Unloading Setup.. ....................................................................... 22 
Figure 8. Bisphosphonate Pre-Treatment Study Design. ................................................. 23 
Figure 9. Ex Vivo pQCT Location Information and Sample Scans. ................................ 26 
Figure 10. Left Tibia 3-Point Bending Experimental Setup (L = 18 mm). ...................... 29 
Figure 11. RPC Location, Sizing Methods, and Setup. .................................................... 32 
Figure 12. Average Weekly Body Weight by Group. Gray region represents HU .......... 36 
Figure 13. Total Bone Mineral Content for Tibia Metaphysis from Ex Vivo pQCT. ..... 39 
Figure 14. Total Bone Mineral Density for Tibia Metaphysis from Ex Vivo pQCT. ...... 40 
Figure 15. Cancellous Bone Mineral Content for Tibia Metaphysis from Ex Vivo 
pQCT. ............................................................................................................... 41 
Figure 16. Cancellous Bone Mineral Density for Tibia Metaphysis from Ex Vivo 
pQCT. ............................................................................................................... 42 
Figure 17. Cortical Bone Mineral Content for Tibia Metaphysis from Ex Vivo pQCT. . 43 
Figure 18. Cortical Bone Mineral Density for Tibia Metaphysis from Ex Vivo pQCT. . 44 
Figure 19. Total Bone Area for Tibia Metaphysis from Ex Vivo pQCT. ........................ 47 
vii 
 
  
  Page 
Figure 20. Cortical Bone Area for Tibia Metaphysis from Ex Vivo pQCT. .................... 48 
Figure 21. Endocortical Area for Tibia Metaphysis from Ex Vivo pQCT....................... 49 
Figure 22. Polar Area Moment of Inertia for Tibia Metaphysis from Ex Vivo pQCT. ... 50 
Figure 23. Cortical Bone Mineral Content for Tibia Diaphysis from Ex Vivo pQCT. ... 53 
Figure 24. Cortical Bone Mineral Density for Tibia Diaphysis from Ex Vivo pQCT. .... 54 
Figure 25. Endocortical Area for Tibia Diaphysis from Ex Vivo pQCT. ........................ 56 
Figure 26. Cortical Bone Area for Tibia Diaphysis from Ex Vivo pQCT. ...................... 57 
Figure 27. Polar Area Moment of Inertia for Tibia Diaphysis from Ex Vivo pQCT. ...... 58 
Figure 28. Bone Strength Index for Tibia Metaphysis from Ex Vivo pQCT. .................. 61 
Figure 29. Stress-Strain Index for Tibia Diaphysis from Ex Vivo pQCT. ....................... 62 
Figure 30. Maximum Force for Tibia in 3-Point Bend Test. ........................................... 65 
Figure 31. Stiffness for Tibia in 3-Point Bend Test. ........................................................ 66 
Figure 32. Energy to Fracture for Tibia in 3-Point Bend Test. ........................................ 67 
Figure 33. Displacement at Fracture for Tibia in 3-Point Bend Test. .............................. 68 
Figure 34. Post-Yield Displacement for Tibia in 3-Point Bend Test. .............................. 69 
Figure 35. Ultimate Stress for Tibia in 3-Point Bend Test. .............................................. 71 
Figure 36. Modulus for Tibia in 3-Point Bend Test. ........................................................ 72 
Figure 37. Pre-Yield Toughness for Tibia in 3-Point Bend Test. .................................... 73 
Figure 38. Maximum Force for Tibia Metaphysis in RPC Test. ...................................... 76 
Figure 39. Stiffness for Tibia Metaphysis in RPC Test. .................................................. 77 
Figure 40. Ultimate Stress for Tibia Metaphysis in RPC Test. ........................................ 80 
Figure 41. Modulus for Tibia Metaphysis in RPC Test. .................................................. 81 
 
viii 
 
  
LIST OF TABLES 
 
  Page 
Table 1. Complete Study Termination Plan. .................................................................... 24 
Table 2. Densitometric Properties Measured at the Proximal Tibia Metaphysis. ............ 38 
Table 3. Geometric Properties Measured at the Proximal Tibia Metaphysis ................... 46 
Table 4. Densitometric Properties of the Tibia Mid-Diaphysis. ...................................... 52 
Table 5. Geometric Properties of the Tibia Mid-Diaphysis ............................................. 55 
Table 6. Strength Indices from Tibia pQCT Data. ........................................................... 60 
Table 7. Extrinsic Mechanical Properties from Tibia 3-Point Bending. .......................... 64 
Table 8. Intrinsic Mechanical Properties from Tibia 3-Point Bending. ........................... 70 
Table 9. Extrinsic Mechanical Properties from Tibia RPC. ............................................. 75 
Table 10. Intrinsic Mechanical Properties from Tibia RPC. ............................................ 79 
Table 11. Comparison of Percent Differences in Means from AC at the End of 
Hindlimb Unloading for pQCT and RPC Measurements. ................................ 92 
ix 
 
  
1. INTRODUCTION 
With the advent of spaceflight, humanity has used the power of scientific 
understanding to overcome a host of difficulties. From rocket propulsion to growing 
food in space, an increased understanding of space has improved humanity’s 
understanding of how to do things on Earth. One such challenge that has a profound 
impact outside of space travel is the performance of bone in space. Due to the 
mechanical unloading that accompanies microgravity in space, the musculoskeletal 
system undergoes significant changes [1] that can lead to bone mass losses on the order 
of 1-1.5% per month [1] - [6].  
There are a variety of ways to combat bone loss that occurs in space. This includes 
exercise [7] - [9], drug interventions [7], [8], [10], and even dietary measures [6], [11]. 
Specifically, when it comes to drug interventions, LeBlanc et al. investigated using a 
bisphosphonate treatment of alendronate in conjunction with aerobic exercise on 
astronauts aboard the International Space Station [8]. Alendronate is a common 
treatment for osteoporosis and has been shown to be effective in reducing fracture risk in 
postmenopausal women. It has also been shown in human bed rest [12], rat hindlimb 
unloading (HU) [13], [14], and human spaceflight [8] to be an effective bone loss 
intervention when administered concurrently with disuse. The current study was 
designed to analyze the effect of bisphosphonate pre-treatments on rats prior to a period 
of HU and, following unloading, a return to normal ambulation. 
Bone is a complicated biological structure that is constantly changing to adapt to its 
environment. Exposure to microgravity causes an overall reduction in skeletal loading, 
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and bone responds by reducing bone mass to meet the new loading requirements. Bone 
is primarily able to adapt through a process known as remodeling. Bone remodeling is 
split into two mechanisms, resorption and formation. During resorption, old bone tissue 
is removed from the matrix. Formation follows resorption and is the process by which 
new bone tissue is added. Under ordinary circumstances, the processes of formation and 
resorption are coupled together in such a way that there is not a net change in bone mass. 
For this reason, remodeling is also referred to as bone homeostasis. This is an important 
aspect of bone’s response to environmental stimuli and it results in changes to bone 
structure and architecture. One method to reduce spaceflight induced bone loss is to 
modify remodeling with drug interventions such as bisphosphonate treatments.  
Bisphosphonates are used to combat the effects of age-related bone loss that occurs 
due to osteoporosis [15]. These drugs work by slowing and even stopping bone 
resorption [16]. This means that, in addition to halting resorption, the formation that 
occurs to complete the cycle of remodeling does not occur. The only growth that 
continues to occur is due to modeling, formation that occurs independent of resorption, 
and not from remodeling. Blocking resorption is an effective countermeasure against age 
related decline [15], but is not without its drawbacks. As the average life span increases 
and the age at onset of osteoporosis is similar, the duration of drug treatment to prevent 
fracture continues to increase. There is an increasing amount of concern that extended 
use of these drugs over long periods of time can actually reverse improvements in 
fracture risk reduction [17], [18]. Clinically, it is now being recommended to for some 
patients to take a hiatus from drug treatment so that the bisphosphonate stored in bone 
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gets depleted allowing bone remodeling to begin again. This can mitigate an excessive 
buildup of old bone tissue which has been linked to rises in fracture risk during 
bisphosphonate treatment [17], [18]. This drug holiday is merely a means to reduce 
potential negative side effects of long term bisphosphonate use. Bisphosphonates are still 
a viable, effective means to reduce fracture risk in patients with a variety of conditions.  
The current investigation was designed to examine at the effects of two 
bisphosphonates and their persisting effects on spaceflight induced bone loss. This was 
studied by using a bisphosphonate drug pre-treatment before a period of HU. While a 
drug pre-treatment does not exactly emulate the current countermeasures that are used to 
combat mechanical unloading, it is still completely relevant and has a few advantages. 
By using a pre-treatment, it is possible to understand how the persisting effect of 
bisphosphonates will impact bone during HU. The effects will persist through the return 
to weight bearing post-HU and will shed light on how bisphosphonates effect the 
recovery of bone. A pre-treatment protocol is also optimal for possible animal 
spaceflight experiments, by limiting astronaut crew time involved with the experiment 
inflight to a minimum. Although not explored in this study, there are also a variety of 
negative side effects from bisphosphonate treatment. A pre-treatment could possibly be 
used to prevent some of these side effects from occurring while in space, where some 
side effects could prove to be much more problematic than on earth.  
This study also sought to examine the effectiveness of bisphosphonate drug pre-
treatments by comparing two bisphosphonates with different binding affinities, 
alendronate and risedronate. The hypothesis was centered on the idea that the long 
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retention times of bisphosphonates would allow the drugs to continue to be effective 
after treatment through a period of HU. After a 28-day pre-treatment, 6 month-old, 
Sprague-Dawley, male rats were exposed to a 28-day period of HU. HU is used to study 
bone loss in a variety of animals. A rat model was chosen, not only for its feasibility, but 
because the bone loss observed in the rat model matches the magnitude of the bone loss 
in human spaceflight when minimal countermeasures are taken to combat spaceflight 
induced bone loss [19], [20]. After HU, the rats were allowed to reambulate and recover 
for 56 days. It was additionally hypothesized that risedronate would show a decline 
quicker than alendronate, which would give it an advantage over alendronate during the 
recovery period. These time periods corresponded with the four termination time points: 
baseline, end of pre-treatment (day 28), end of HU (day 56) and end of recovery (day 
112). The study utilized an unbalanced design, with an age matched control that had no 
treatment, and an HU control group that was unloaded but had no pre-treatment. All of 
the animals given alendronate and risedronate underwent HU. 
The area of interest when studying human bone is typically the femoral neck or the 
lumbar spine. The femoral neck has been shown to be an incredibly dangerous area of 
fracture in postmenopausal osteoporosis [21] and has been an area of focus for 
spaceflight induced bone loss [3]. For rats, the sites that best replicate the bone 
composition as seen in the human femoral neck are the proximal tibia metaphysis [22] 
and the distal femur metaphysis. The site of primary interest in this study is the proximal 
tibia metaphysis, but the tibia mid-diaphysis will also be examined. 
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The left tibia of all of the rats was analyzed post mortem with three different 
techniques. These techniques included peripheral Quantitative Computed Tomography, 
3-point bend mechanical testing, and reduced platen compression mechanical testing. 
Each of these techniques offer a unique look at how differences in mineralization, 
geometry and mechanical strength were caused by changes in treatment. The differences 
between these methods of analysis will offer insight into how the rat bone changes based 
on treatment and time. With the analysis of the data from this rodent model, it could be 
possible to better understand methods to prevent spaceflight induced bone loss and 
understand how two different bisphosphonates affect bone strength.  
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2. OBJECTIVES 
This investigation has two major areas of interest. The first is to understand how the 
two drug pre-treatments alter bone during hindlimb unloading (HU) and recovery. The 
second focus is to see what differences, if any, arise between the use of alendronate and 
risedronate. The objectives of this investigation were as follows: 
1. To characterize the effects of two different bisphosphonate treatments 
administered prior to a bout of HU on both a period of HU and a period of 
recovery using densitometric and geometric properties of the rat left tibia.  
2. To characterize the effects of two different bisphosphonate treatments 
administered prior to a bout of HU on both a period of HU and a period of 
recovery using mechanical properties of the rat left tibia.  
3. To further understand how changes in densitometric properties compare to 
changes in intrinsic and extrinsic mechanical properties.  
Based on these objectives, I hypothesize that both bisphosphonate pre-treatments 
before unloading will protect against bone loss, particularly in the cancellous region, 
during the subsequent unloading period. The use of a bisphosphonate pre-treatment will 
not hinder the recovery of bone upon return to weight bearing following unloading.  
Additionally, I also hypothesize that if differences arise between the drug pre-
treatments, risedronate will show a more positive affect over recovery compared to 
alendronate upon return to weight bearing. ALN will be more likely to negatively impact 
the recovery process because its higher binding affinity will introduce stronger and more 
persistent suppression of remodeling. 
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3. BACKGROUND 
This experiment was conducted as part of a larger study funded by the National 
Aeronautics and Space Administration (NASA) as a part of NASA Space Biology grant 
number #NNX13AM43G. The aim of the study was to assess the efficacy of two 
different drug pre-treatments to combat space flight induced bone loss and recovery 
from space flight. This was done using a rat hindlimb unloading (HU) model. The model 
utilized a 28-day period of unloading followed by 56 days of return to normal 
ambulation (recovery). The treatments used in the study were two anti-catabolic drug 
treatments, both bisphosphonates, alendronate (ALN) and risedronate (RIS). This 
experiment was focused on understanding changes in the tibia by using two different 
methods of measuring mechanical and densitometric properties. The data collected will 
offer insight into how the two bisphosphonate drugs affect skeletal integrity in the long 
term, and, especially, for astronauts. These results will offer new and insightful results 
that can be used to better inform decisions about how to treat astronauts in space, and 
how to treat other users of bisphosphonates on earth. 
3.1.  The Basics of Bone Biology 
Bone is the part of the body that gives it shape and structure. Like every other part of 
the body, it has the ability to adapt to the environment around it, which makes it truly 
impressive. Bone is composed of two different types of bone, cortical and cancellous 
bone.  
Cortical bone is largely composed of a mineralized collagen framework made up of 
an interior of calcium phosphate and water. This structure is organized in a lamellar 
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fashion that is initially determined by a genetic model [23]. These layers form 
cylindrical structures known as osteons (Figure 1). Osteons are concentric layers of 
cortical bone that surround what is known as the Haversian canal. This canal houses 
vessels and nerves and is used to deliver nutrients to the interior of the bone.  
 
 
Figure 1. Sketch of Important Features of Long Bone. [23] 
 
An important thing to consider for this experiment is that Haversian canals and 
osteons are not present in rat cortical bone [23]. This is an important difference between 
the actual structure and behavior of rat bone compared to human bone. This limits the 
scope of comparison between humans and rats for the study of intracortical bone 
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remodeling, but rat models are very effective in predicting the outcomes of similar 
treatments to human cancellous bone.  
The other type of bone is cancellous bone as shown in Figure 2. This bone is unique 
in that it is made of individual trabeculae which form a porous network [23]. It can be 
found in vertebrae, flat bones, and the ends of long bones. This bone is 75-95% porous 
with marrow cells filling the interconnected pores. These pores are formed by individual 
trabeculae that are around 200 μm thick [24]. The structure of the trabeculae is unique in 
a few ways. The first is that all animals show the exact same size of trabeculae [24]. This 
means that the only difference between humans and rats is the volume of cancellous 
bone, not the actual size of the trabeculae that make up the bone.  
 
 
 
Figure 2. Diagram of Cortical and Cancellous Regions of Bone. [25] 
 
Cancellous bone is a region of bone that also shows the most rapidly, depending on 
the local environmental conditions. It is widely believed that the trabeculae in these 
compartments are able to align themselves so that they are in the direction of maximum 
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loading [26], [27]. Cancellous bone is useful because individual trabeculae are smaller 
than the layers that make up cortical bone, meaning that it can be modified quickly, 
through bone resorption or formation, to adapt to the environment. The porous structure 
of the bone allows it to absorb more impact than cortical bone and that is why it can be 
found in the locations it is throughout the body; these are locations of high impact such 
as the long bones and spine. 
These descriptions of cortical and cancellous bone are missing a very important part, 
the biology behind how they work. Bone is more than just a structural support. It is a 
living part of the body that is constantly changing. Bone undergoes two processes that 
make up this cycle of change: formation and remodeling. 
Bone formation is basic growth of bone. Bone is added layer by layer in a lamellar 
structure. This process occurs at a high rate during early development and once skeletal 
maturity is reached, the rate of formation slows [23]. The occurrence of bone formation 
remains relatively constant after skeletal maturity, except during cases of fracture 
healing or other severe damage to the bone. 
Remodeling is the process by which bone adapts to environmental conditions. This 
process involves a three step cycle: activation, resorption and formation [23]. In 
activation, osteoclasts, a specialized bone cell, begin to move to sites in the bone where 
tissue is to be removed. In resorption, the osteoclasts work to remove the old tissue. In 
formation, another bone cell, known as an osteoblast, replaces the removed tissue with 
new bone. This process is shown in Figure 3. This process seems simple in concept, but 
understanding this process and how it affects bone is a large area of research in bone 
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biology. Small changes in hormones and other regulatory functions in the body can 
drastically effect the way that osteoclasts and osteoblasts behave. This experiment, 
which uses hindlimb unloading, is also looking at how changes in remodeling or after a 
period of disuse affect the resulting bone structure.  
 
 
Figure 3. Osteoclasts and Osteoblasts in the Bone Remodeling Cycle. 
 
 
When experiencing spaceflight or hindlimb unloading, bone adapts to the lack of 
mechanical loading on the skeleton by removing bone. This would not be a major 
problem if astronauts were to stay in space; however, if the skeleton is completely 
adapted to space, it will not be able to handle the much higher mechanical load on the 
skeleton due to earth’s gravity at the end of a mission.  
3.1.1. Mechanical Adaptation of Bone  
Changes in the loading of bone can drastically alter how bone is structured. Bone can 
undergo a wide variety of adaptations and depart greatly from what could be called 
“normal” structure. These changes are described by what is known as Wolff’s law. This 
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law states that bone in all vertebrates will adapt to the current mechanical loading 
conditions to which it is subjected [28]. This means that as loading changes, formation 
and remodeling are used to modify both the cortical and cancellous bone. This ability to 
alter bone is based on what is known as mechanotransduction. There are special cells in 
the bone matrix that are able to detect changes in loading and these then instruct the 
osteoclasts and osteoblasts to begin their work in new formation and remodeling. In 
unique cases, these changes can cause bone to change so rapidly that it does not structure 
itself in a lamellar fashion. 
The process of HU triggers a response in the mechanotransduction cells that causes a 
drastic increase in resorption, resulting in rapid bone loss. This is a risk because, upon 
returning to earth, astronauts no longer have the bones with the same strength as when 
they departed to space.  
3.2. Understanding Mechanical Testing Data 
Destructive testing of materials can be useful in understanding how and why they 
fail. This is especially useful in understanding the mechanical strength of bone. 
Mechanical testing allows bone fracture risk to be explored in much more depth. This 
not only includes the maximum stresses that a material can withstand, but how much 
deformation the material can undergo and how the progression of deformation reflects 
other properties of the material. Figure 4 shows a typical mechanical testing output that 
is used to measure mechanical properties.  
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Figure 4. Graphical Representation of Extrinsic Force-Displacement Data with 
Important Data Markers. 
 
 
There are three important points in Figure 4. The most basic two points are the point 
of maximum force and the point of fracture force. The other point is the yield point. This 
point is where the material begins to undergo irreversible changes. This point marks the 
point of plastic deformation. The linear region to the left of this point is where elastic 
deformation occurs. The yield point is defined by the end of this linear region of 
deformation.  
The area under this curve is used to calculate energy, sometimes referred to as work. 
This is the amount of energy that the material is able to absorb. For instance, if the area 
was calculated from the yield point to the fracture point this would be the energy from 
Displacement (mm)
Lo
ad
 (N
)
Yield Point
Max Force
Fracture Point
Energy to Fracture
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yield to fracture. Energy can be used to compare how the material undergoes 
deformation and can be used to determine if the material is ductile or brittle.  
These material properties are only extrinsic properties. This means that these are 
measured values that are independent of any contributing factors that could vary 
between specimens. For example, these properties do not take into account any aspect of 
the geometry of the specimen tested. For this experiment, the intrinsic properties are 
directly related to the varying cross-sections of the specimens tested. The 3-point bend 
test uses cross-sectional moment of inertia and the reduced platen compression test uses 
area to calculate intrinsic properties from the directly measured extrinsic properties.  
Since these intrinsic measurements depend on the cross-section, that means that there 
can be differences seen in these properties even if the extrinsic properties show no 
difference. Due to the fact that the drugs used in this study are both bisphosphonates, 
their method of intervention is incredibly similar. When it comes to finding differences 
between the drugs, the comparison of extrinsic and intrinsic properties will offer an 
interesting perspective on how the drugs may be affecting the bone in different ways.  
3.3. The Effect of Bisphosphonates on Bone Biology 
This experiment used two different bisphosphonate drug treatments to combat the 
induced bone loss of hindlimb unloading. Bisphosphonates are a catabolic treatment 
used to combat osteoporosis [15]. These drugs work by slowing and even stopping bone 
resorption and only allowing new bone formation [16]. In other words, bone is allowed 
to grow, but not allowed to resorb old bone tissue. There is not a complete consensus on 
whether the bisphosphonates act directly on the osteoclasts or the osteoblasts [16], but it 
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is generally considered to affect the osteoclast. The drug works by binding to 
hydroxyapatite in the matrix of the bone. During resorption, old crystals are dissolved 
and this releases the bisphosphonate. This is the point where the drug begins to take 
effect. Since these drugs take effect after osteoclasts begin the resorption process, they 
do not limit primary formation of bone; however, they do suppress overall formation 
because formation due to remodeling is essentially halted. Remodeling is the main 
source of formation after skeletal maturity is reached. This process is shown in Figure 5. 
In the context of this study, this means that the effect of the drugs will not be 
pronounced until massive resorption begins, during HU. 
 
 
Figure 5. Bisphosphonates and the Remodeling Cycle. 
 
There are a few other important things to note about bisphosphonates. First, is that 
because the drugs need a surface to bind to, the high surface area of the cancellous 
region is an optimal site for the drugs to bind. Another important bisphosphonate 
X Bisphosphonate incorporated in hydroxyapatite 
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specific effect is binding affinity. This is simply how well the drug can bind to the 
hydroxyapatite. High binding affinity drugs are unable to penetrate as deep into the bone 
matrix because they bind very rapidly. Low binding affinity drugs are able to penetrate 
deeper into the matrix because they do not bind as readily to hydroxyapatite [29]. 
The drugs also have another interesting effect. Since they have to be dissolved out of 
the matrix to be released, they remain in the mineralized for quite some time. Some of 
the drugs have been shown to remain in the skeleton for an incredibly long time [30], 
[31], depending on the treatment procedure. The clinical effectiveness of these drugs is 
based on their binding affinity [30]. The binding affinity and the retention time in the 
skeleton are directly related and the higher the binding affinity [31], the more clinically 
effective the drug is considered to be [32]. 
The only remaining thing to consider in regards to binding affinity is how it affects 
the initial time of the treatment. There are differences in the effect of some of the drugs 
depending on the method of administration. Injections have shown to be the best method 
for treatment as they limit secondary complications and do no inhibit the effectiveness of 
the drug [16]. Bisphosphonates have poor absorption through oral administration, and 
this limitation does not seem to vary between drug binding affinities [16]. There also 
does not seem to be a relationship between initiation of the effects of bisphosphonates 
and binding affinity. 
An interesting aspect of a bisphosphonate treatment is how exercise can modify the 
effects of the treatment. Studies have shown that resistance exercise [33] and regular 
exercise [34] did not alter the results of the drug treatments. The combination of 
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alendronate and resistance exercise have been tested in space and the results indicated 
that this can greatly reduce bone loss [8]. Unfortunately, there is no data to compare this 
to a group treated with only bisphosphonates during spaceflight. 
These drugs are an effective countermeasure against age-related decline [16] in bone 
mass, but not without any drawbacks. As the average life span increases, the duration of 
drug treatment to prevent fracture continues to increase. A concern arises from the fact 
that bisphosphonates eventually begin to limit new formation and can cause an increase 
in bone brittleness. This change in bone is due to the overall lack of formation. Since 
new bone formation slows after skeletal maturity, this becomes the only method of bone 
formation once remodeling, which has a secondary method of bone formation, is halted 
by bisphosphonate treatment. Clinicians have become increasingly concerned about how 
these changes could affect bone over a long period of time. The concern is that the 
extended use of bisphosphonates over long periods of time could actually reverse 
improvements in fracture risk reduction [17]. 
These drugs can be used for a variety of situations involving bone loss and have 
previously been used on NASA missions aboard the International Space Station. They 
have been shown to work to combat bone loss effectively in both astronauts and 
comparable rat hindlimb unloading models. Therefore, this study seeks to build upon 
this body of research to discover how the lingering effect of two different 
bisphosphonate pre-treatments will affect bone during a subsequent period of hindlimb 
unloading and recovery.  
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4. EXPERIMENTAL METHODS 
This experiment examined the ability of pre-treatments to improve the performance 
of bone in space. The study used two bisphosphonate drug treatments as interventions 
against bone loss, alendronate and risedronate. Effects of the treatments on the left tibia 
were evaluated using peripheral Quantitative Computed Tomography (pQCT), and two 
tests to measure bone mechanical properties: 3-point bending, and reduced platen 
compression (RPC) testing.  
4.1. Animal Study Background 
This experiment used 140 Sprague-Dawley rats acquired from Harlan Sprague 
Dawley Inc. (Houston, TX) as a part of a protocol approved by the Institutional Animal 
Care and Use Committee (IACUC). The rats were purchased at approximately 5.5 
months old where they have reached skeletal maturity. They were allowed to acclimate 
for two weeks before beginning the study. After acclimation, the animals were divided 
into different treatment groups based on body weight and total volumetric bone mineral 
density (vBMD) from in vivo pQCT at the proximal tibia.  
The use of a pre-treatment does not actually emulate the typical countermeasures that 
are used to combat the unloading effects of microgravity, which are implemented 
concurrently with spaceflight. Instead, it was used to characterize the time course of 
effects through a period of HU and recovery following HU. This recovery period is a full 
return to complete normal weight bearing and ambulatory activity. The protocol was 
optimized for potential animal spaceflight experiments, by eliminating astronaut crew 
time required for the experiment as would be the case with a concurrent treatment. This 
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experiment was additionally aimed at comparing the efficacy of two bisphosphonates 
with different binding affinities. This investigation has broader implications outside of 
space flight because of the use of these two drugs. These drugs are widely used to treat 
osteoporosis but also periods of prolonged disuse, such as bed rest, show comparable 
effects of bone loss that could possibly be treated with the use of these treatments.  
4.1.1. Choice of Bisphosphonates 
The major point of treatment comparison centered around two different 
bisphosphonate drugs. One of the drugs, alendronate, was chosen based on past usage in 
spaceflight [8]. It is also a common method for treating postmenopausal osteoporosis 
and is one of the most widely used bisphosphonates. The only issue with the past usage 
in space is that it was tested in conjunction with exercise and it was not ever used as a 
singular intervention in space. For this reason, it is not clear what the extent of the 
effects of the drug are in space. This study sought to use this drug to better understand its 
effect on microgravity bone loss with a rat hindlimb unloading study. 
The other drug, risedronate was selected based on its binding affinity. Binding 
affinity simply refers to how tightly the bisphosphonate binds to the ligand which is 
solely a characterization of intermolecular forces between the bisphosphonate and the 
hydroxyapatite. It is important to note that binding affinity is a determinant of the 
duration of bisphosphonate effectiveness and does not necessary offer any indication of 
potency. Risedronate has a lower binding affinity than alendronate, which allows this 
study to investigate how differences in binding affinity will affect the observed changes 
in bone over HU and recovery. The expectation is that the differences in binding affinity 
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may cause a difference between risedronate and alendronate to become apparent over the 
course of the study. Due to differences in the lingering effects of the two pre-treatments, 
it is possible that risedronate could provide a better overall response. The lower binding 
affinity could reduce the chances of inhibiting the recovery that needs to occur in bone 
upon return to weight bearing.  
4.1.2. Comparing Rat and Human Bone 
There are several important things to consider when trying to interpret these results 
and put them in the context of the implications of these results in terms of human 
spaceflight. The first of these is comparisons between rat and human aging. Correlating 
rat to human ages can be difficult because rat development varies widely during their 
lifespan; but, during the period of HU, 10-15 rat days roughly correspond to 1 human 
year [35]. This means that the 28 day HU is roughly equivalent to 2 years in terms of 
humans.  
Typically, over this 28 day HU period, bone responses similarly to astronauts taking 
minimal countermeasures to combat bone loss. The HU model in 6-month old rats shows 
bone loss during 28-days in accordance with 4-6 months of astronaut spaceflight. 
Previous work by Shirazi et al. demonstrated these results [8], [22]. 
One of the major sites of concern for fracture risk in humans is the femoral neck. 
This location has a thin cortical shell that surrounds a central region made up of 
cancellous bone. In the rat, the femoral neck is mainly cortical bone. This can be seen in 
Figure 6.  
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Figure 6. Diagram of Human and Rat Proximal Femur. [36] 
 
The rat proximal tibia metaphysis better expresses the combination of cortical and 
cancellous bone that more closely mimics the human femoral neck, so this region was 
selected as the region of focus to analyze how the changes here could potentially affect 
the human femoral neck. While these comparisons are less than perfect, it has been 
shown that this is a good analog to humans because rat bone behavior at this site on the 
cellular and structural level mirrors human bone biology [37].  
4.2. Experimental Design 
The animals were block assigned to four groups based on body weight and total bone 
mineral density at the proximal tibia metaphysis in order to create equivalent baseline 
measurements across all groups. There were two control groups, an age-matched cage 
control (AC) and a hindlimb unloading control (HUC). There were also two drug 
treatment groups (ALN and RIS) that also underwent HU after receiving the drug pre-
treatment.  
21 
 
  
The HU method follows a protocol modified from the Morey-Holton tail traction 
method [5]. A custom-made harness is affixed to the tail of the animal so that the 
hindlimbs no longer contact the cage bottom (Figure 7a). The rat is suspended at a 30° 
head-down tilt; the front limbs still retain full contact with the cage bottom. A hook at 
the end of the tail harness connects to a pulley and rod system in the cage (Figure 7b) so 
the animal has the ability to move about the cage to access food and water with only its 
front legs.  
 
 
(a) 
 
(b) 
Figure 7. Rat Hindlimb Unloading Setup. (a) Rat in Hindlimb Unloading Harness 
(b) Hindlimb Unloading Cage. 
 
 
The animals receive a health check twice daily during the 28-day HU period. After 
completing HU, the animals were given 56 days to recover. During recovery, the rats 
return to their pre-study regular ambulation and weight bearing. All rats were single 
housed throughout the duration of the study and were provided standard rodent chow 
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(Harlan Teklad 8604) and water ad-libitum, except where specified. When not 
undergoing HU, the rats were housed in the standard shoebox cages. 
The study design was laid out in 28-day (1 month) increments. The first 28 days 
consisted of the drug pre-treatment. The drug treatment groups were given subcutaneous 
injections tri-weekly for four weeks. The ALN dosage was 2.4 μg/kg. The RIS dosage 
was 1.2 μg/kg. These doses correspond, respectively with 10 ng/d and 5 mg/d clinical 
does given to treat postmenopausal osteoporosis in humans [38]. Upon reaching the 28th 
day of the study, HU of the animals began.  
There were four important time points in the study that were used to measure the 
effects of the treatments in excised bone as shown in Figure 8. Bone tissue was collected 
from separate groups of rats terminated at, baseline (day 0), the end of pre-treatment 
(day 28), the end of HU (day 56) and the end of recovery (day 112). 
 
 
Figure 8. Bisphosphonate Pre-Treatment Study Design. 
 
 
The termination plan of the study is shown in Table 1. Eight AC rats were terminated 
at each time point. The HUC animals there were 10 rats terminated, but only at days 56 
and 112. To streamline the study design, no HUC animals were terminated at day 0 or 
28, because no animals had undergone HU until after day 28. The two drug treatment 
groups had terminations of 15 animals per days 28, 56, and 112. The unbalanced design 
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was used as part of a larger experiment where both the HUC and AC groups will 
eventually be filled out to have 15 rats per time point. The time point size of 15 per 
group was chosen to provide enough power to accurately measure the treatment effects 
in mechanical testing. 
 
Table 1. Complete Study Termination Plan. 
 
  Baseline End of Pre-Treatment End of HU End of Recovery 
AC 6 8 8 8 
HUC - 10 10 10 
ALN - 15 15 15 
RIS - 15 15 15 
 
 
4.2.1. Hindlimb Unloading 
HU is the method used in this experiment to induce bone loss on a level similar to 
that of spaceflight. The model causes bone loss that matches the magnitude of bone loss 
in astronauts when minimal countermeasures are taken to combat spaceflight induced 
bone loss [19], [20]. New measures are always being tested to help astronauts improve 
bone health in space, and this model is widely used to understand new ways of tackling 
this problem. 
The model correlates well to spaceflight because the lack of weight bearing causes 
the bone to modify itself to meet the new loading conditions. The model also produces 
effects on the cardiovascular, immune, renal, neural, metabolic and reproductive systems 
that mimic spaceflight [19]. The changes in loading due to HU mean that bone loss 
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occurs because the skeleton no longer carries the same mechanical load needed to 
support the body. These rapid changes are marked by a dramatic increase in resorption 
and a suppression of bone formation [19]. Not only is the HU model a well-established 
and accepted ground based model for simulating the effects of microgravity, but it other 
serious advantages over other methods of simulating microgravity. This model was 
chosen over onabotulinum toxin A, and other methods of disuse because of the 
feasibility of a rodent model. Human bed rest studies can be incredibly costly and 
astronaut studies of bisphosphonates have also been very limited in data collection due 
to small sample sizes. The model was also chosen because of the good correlation 
between HU and the wide variety of changes seen in astronauts. 
4.3. Ex Vivo Peripheral Quantitative Computed Tomography of Tibia 
Each left tibia was analyzed to assess the levels of mineralization, measure various 
geometrical parameters, and estimate strength indices of the bone using ex vivo 
peripheral Quantitative Computed Tomography (pQCT). The tibia was scanned using a 
Stratec XCT 3000 (XCT Research M Stratec; Norland Corp., Fort Atkinson, WI). Using 
a voxel size of 70 μm, four scan lines 0.5 mm thick were completed in the metaphysis 
region beginning 4.25 mm distal from the tibia plateau. This region was chosen to avoid 
the growth plate, which is not as responsive to hindlimb unloading, and focus on the 
region of cancellous bone tissue. The scan locations are shown in Figure 9, along with 
sample output images. An additional scan was taken at the mid-diaphysis of the bone, 
half of the length of the bone.  
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(a) 
 
(b) 
 
(c) 
 
(d) 
 
Figure 9. Ex Vivo pQCT Location Information and Sample Scans. (a) Ex Vivo 
pQCT Scan Locations; Sample Image of pQCT at: (b) proximal tibia metaphysis 
(c) tibia mid-diaphysis (d) Regions of Analysis: Total Area (Blue + Green), Cortical 
(Blue), and Cancellous (Green). 
 
 
In order to differentiate between cortical and cancellous bone contour and peel 
algorithms were used. These algorithms were provided by Stratec XCT software (v6.00, 
Norland Corp., Fort Atkinson, WI). The contour algorithm differentiates between 
density of cortical bone and surrounding fluid. The peel algorithm is used to delineate 
between the cortical and cancellous bone at the endocortical surface. The contour and 
1 mm 
1 mm 
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peel thresholds for the metaphysis were 450 g/mm3 and 800 g/mm3 respectively. The 
thresholds for the diaphysis were 650 g/mm3 for both algorithms. 
4.3.1. Peripheral Quantitative Computed Tomography Output Parameters 
The parameters generated from this analysis method included the densitometric 
outcome variables bone mineral content (total, cortical, and cancellous) and bone 
mineral density (total, cortical, and cancellous). The pQCT data also included 
geometrical properties such as polar moment area of inertia (PAMOI), and cross-
sectional areas (cortical, cancellous and total). Bone mineral content (BMC), volumetric 
bone mineral density (vBMD), and cross-sectional area were determined for each of the 
three regions of the cross-section (Figure 9d): cortical, cancellous, and total. The total 
region is sometimes referred to as integral for BMC and vBMD because they include 
contributions from both the cortical and cancellous regions.  
 In addition to geometric and mineral measurements, strength indices were derived 
using area and density properties. These indices are meant to be an estimated measure of 
mechanical strength. The bone strength index (BSI) was used to estimate the 
compressive strength of the tibia at the metaphysis. This is shown in Equation 1 and was 
compared to the results of the reduced platen compression test.  
 
𝐵𝐵𝐵𝐵𝐵𝐵 = (𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝐴𝐴𝐴𝐴𝐴𝐴𝑡𝑡)(𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑣𝑣𝐵𝐵𝑣𝑣𝑣𝑣)2 Equation 1 [3] 
 
The stress strain index (SSI) uses total bone mineral density as substitute for 
modulus and multiplies this value times the moment of inertia of the cross-section. This 
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value correlates roughly to the section modulus in beam theory (Equation 2). The SSI is 
given in Equation 3. The measurement made in this experiment is the polar SSI, which 
eliminates differences due to bone alignment in the scanning bed. 
 
𝑍𝑍 = 𝐵𝐵
𝑐𝑐
 Equation 2 
𝐵𝐵𝐵𝐵𝐵𝐵 = �𝐴𝐴𝑖𝑖2𝑡𝑡𝑖𝑖 𝐶𝐶𝑣𝑣𝑖𝑖𝑁𝑁𝑣𝑣  
𝐴𝐴𝑚𝑚𝑚𝑚𝑚𝑚
  Equation 3 [39] 
 
 
The section modulus includes I, the moment of inertia, and c, the maximum distance 
from the bending axis to the outer edge of the beam. This parameter is meant to describe 
the bending stiffness. The SSI measurement (Equation 3) is a voxel-by-voxel summation 
used to estimate section modulus. In this measurement, ri is the voxel distance from the 
center of mass, ai is the voxel area, CDi is the apparent voxel density, ND is the normal 
density of cortical bone (this is assumed to be a value of 1200 mg/cm3), and rmax is the 
maximum distance between the density-weighted center of mass and the outermost voxel 
for the entire cross-section. The difference between this measurement and section 
modulus is that SSI is density weighted; however, they still reflect the same general 
principles. This value was taken at the diaphysis and compared to the results of the 3-
point bend test.  
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4.4. Ex Vivo 3-Point Bend Test of Tibia 
Upon completing ex vivo pQCT scans, a 3-point bend test was used to evaluate the 
mechanical properties of the left tibia mid-diaphysis. The bones were stored with saline 
and gauze and were thawed to room temperature. Prior to testing digital calipers were 
used to manually determine the anterior-posterior and medial-lateral periosteal diameters 
at the mid-diaphysis for each bone. The length of the bone and the midpoint were also 
recorded. This site is where the center of the bending load is placed, so that the pQCT 
data at the mid-diaphysis will correspond to the loading point. This is done so that the 
measurement of cross-sectional moment of inertia (CSMI) can be used to estimate 
intrinsic mechanical properties in addition to estimating whole bone extrinsic properties. 
The load was applied using an Instron 3345 Single Column Testing System (Norwood, 
MA). Each bone was positioned with the anterior side resting on two supports, each 
spaced 18 mm apart (Figure 10). 
 
 
Figure 10. Left Tibia 3-Point Bending Experimental Setup (L = 18 mm). [40] 
 
Once positioned, a preload of about 1 N was applied to the tibia. The crosshead then 
descended at a rate of 2.54 mm/min (0.1 in/min) and loaded the bones until failure. 
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Force and crosshead displacement were recorded at 50 Hz by Bluehill (version 2.35, 
Instron) using a 1kN Instron load cell (2519-105, Norwood, MA). Post hoc analysis was 
used to determine the intrinsic and extrinsic mechanical properties from the recorded 
force, displacement and bone CSMI data with a custom written MATLAB program 
(version 8.5, The MathWorks, Inc.).  
4.4.1. 3-Point Bend Test Output Parameters 
Extrinsic properties are recorded directly from the output of the 3-point bending test. 
Intrinsic properties are based on inherent properties specific to each material. The 
extrinsic properties reported from this test include maximum load (Fult), stiffness (k), 
post-yield displacement and energy to fracture (Ef). These values were all calculated 
with post hoc analysis. 
Intrinsic properties are derived using Equation 4-Equation 6 using half of the polar 
moment of inertia, (the CSMI, I)  a property that varies between bones. These equations 
are based on classical beam theory for a beam with simple supports at two ends with a 
load applied in the middle. The intrinsic outcome variables of interest for this test were 
ultimate stress (σult), elastic modulus (E) , and pre-yield toughness (𝜇𝜇). 
 
 
𝜎𝜎𝑢𝑢𝑢𝑢𝑢𝑢 = 𝐹𝐹𝑢𝑢𝑢𝑢𝑢𝑢𝐿𝐿𝑐𝑐4𝐵𝐵  Equation 4 
 
𝐸𝐸 = 𝑘𝑘𝐿𝐿348𝐵𝐵 Equation 5 
 
𝜇𝜇 = 𝐸𝐸𝑓𝑓𝑐𝑐2
𝐿𝐿𝐵𝐵
 
Equation 6 
L is the span depth, c is the anterior-posterior diameter and I is the CSMI 
30 
 
  
 
It is important to note that, because of the nature of the assumptions used in the 3-
point bend testing, these intrinsic properties are only estimates. The largest assumption 
involved in this analysis is that the location of the measurement of the CSMI is at the 
exact point of loading. Intrinsic properties are important to consider because they help 
answer the question of how important the geometry (i.e., CSMI) is to the structural 
integrity of the bone. There are also underlying assumptions to the analysis that the cross 
section is of uniform shape across the 18 mm region that is subjected to bending. These 
properties indicate changes of tissue quality that are independent of changes in bone 
mass or bone geometry. 
4.5. Ex Vivo Reduced Platen Compression Test of Proximal Tibia Metaphysis 
The other measure of mechanical strength, reduced platen compression (RPC) 
testing, was used to test the properties of the cancellous portion of the tibia metaphysis. 
This test is fairly complicated and requires machining specimens out of the proximal 
tibia metaphysis before testing. Once the machining is completed, the samples were 
analyzed to determine platen size required for the testing, and finally, the specimens 
were tested.  
4.5.1. Specimen Preparation 
Specimens were machined using a Well Precision Diamond Wire Saw model 3242 
(Well Diamond Wire Saws, Inc., Norcross, GA). A 2 mm region 0.5 mm distal from the 
tibia lateral condyle was removed from the tibia for the RPC test, as shown in Figure 
11a. This region is meant to roughly correspond to the region of interest from pQCT 
31 
 
  
measurements taken at the proximal tibia metaphysis. Prior to testing the specimen, 
photographs were taken of each of the specimens and Adobe Photoshop (Adobe Systems 
Incorporated, San Jose, CA), was used to determine platen size. Prior experience has 
demonstrated that platens should be sized to cover 70% of the diameter of the largest 
circle that can be inscribed into the endocortical perimeter (Figure 11b). 
 
 
 (a) 
  
 
 
 
(b) 
 
 
 
(c) 
 
Figure 11. RPC Location, Sizing Methods, and Setup. (a) RPC Specimen Location 
(shown in red) (b) Platen Sizing Method (c) RPC Test Setup 
 
 
4.5.2. Reduced Platen Compression Test Method 
After preparation, the specimen was compressed between two platens using an 
Instron 3345 Single Column Testing System (Norwood, MA). Force and displacement 
data generated by a 100N Instron load cell (2519-103, Norwood, MA) were recorded 
using Bluehill (version 2.35, Instron) at 20 Hz. The most proximal end of the specimen 
2 mm 
0.5 mm 
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is placed on the bottom platen, while the most distal end of the specimen is loaded with 
the upper platen (Figure 11c). The specimens were loaded at a rate of 0.254 mm/min 
(0.01 in/min) and compressed. This test allowed the mechanical properties of proximal 
tibia metaphysis cancellous bone to be assessed, as it is the only region of direct loading 
in this test. Post hoc analysis was completed using the same custom written MATLAB 
program used for 3-point bending.  
4.5.3. Reduced Platen Compression Test Output Parameters 
The extrinsic variables of interest for this test were maximum force (Fult) and 
stiffness (k). The intrinsic variables of interest for this test were ultimate stress (σult) and 
elastic modulus (E) and strain at yield (ε). They are derived using the equations below 
(Equation 7-Equation 9). These equations calculate the material properties of an isolated 
cylinder in compression. 
 
 
 
𝜎𝜎𝑢𝑢𝑢𝑢𝑢𝑢 = 𝐹𝐹𝑢𝑢𝑢𝑢𝑢𝑢𝐴𝐴𝑝𝑝𝑢𝑢𝑚𝑚𝑢𝑢𝑝𝑝𝑝𝑝 Equation 7 
 
𝜀𝜀 = 𝑑𝑑
𝑡𝑡
 
Equation 8 
 
𝐸𝐸 = σ
𝜀𝜀
= 𝑑𝑑𝐹𝐹𝑦𝑦𝑖𝑖𝑝𝑝𝑢𝑢𝑦𝑦 
𝑡𝑡𝐴𝐴𝑝𝑝𝑢𝑢𝑚𝑚𝑢𝑢𝑝𝑝𝑝𝑝  Equation 9 
 
Where d is crosshead displacement and t is specimen thickness 
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4.6. Statistical Analysis 
The data were evaluated for statistical relationships using R (The R Foundation). The 
statistical analysis of this data was done to compare differences between groups within 
each time point. No differences were tested between time points. Data were checked for 
normality using the Shapiro-Wilk test. Homoscedasticity was evaluated using a Brown-
Forsythe Levene-type test. If the data were determined to be normally distributed, 
comparisons between groups were performed using a one-way ANOVA and a Tukey 
HSD post hoc test. If the Shapiro-Wilk and the Brown-Forsythe hypothesis were not 
rejected, then the comparisons were made using a Kurskal-Wallis rank sum test followed 
by a pairwise Dunn’s Test for median difference. Differences were considered 
significant when p < 0.05. 
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5. RESULTS 
The following plots for each of the four measures will show group means with bars 
representing standard deviations. The x-axis for each plot shows the time duration into 
the study at which each measurement occurred. Time is recorded in days and designated 
with a “d” preceding the numerical day. The gray region on each plot designated the 
period of HU. A solid blue line with a circle is used to represent the control group (AC). 
A short dashed, red line with triangles is used to represent the hindlimb unloading 
control (HUC). A purple, dot-dash line with diamonds is used to represent the 
alendronate group (ALN). Finally, a dashed green line with squares is used to represent 
the risedronate group (RIS). When comparing the time points it is important to note that 
different animals make up each of the reported means as the data was collected ex vivo. 
Due to specimen attrition throughout the study, the number of animals per group per 
time point vary slightly between measurements. The minimum number of animals per 
group is specified by measurement and given at the start of each measurement section. 
Additionally, a breakdown of the statistical analysis by time point for all measurements 
can be found in Appendix A. Appendix B includes additional measurements not 
included in the Results section.  
The efficacy of the treatment is an important thing to mention before elaborating on 
the results of the actual data collection. Animals were weighed twice weekly and the 
body weights are shown in Figure 12.The animals lost some weight over HU but it was 
recovered by the end of the time period. AC animals were pair fed an average value of 
food eaten by the other groups over the period of HU. Several animals were lost over the 
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course of the study. Two ALN and two RIS animals were removed from HU due to 
health concerns. These were the only attritions during the course of treatment.  
 
 
 
Figure 12. Average Weekly Body Weight by Group. Gray region represents HU. 
 
5.1. Ex Vivo pQCT of the Left Tibia 
Ex vivo pQCT scans were completed at the left tibia for each group at all time 
points. Four scans were taken at the proximal metaphysis and one scan was taken at the 
mid-diaphysis. For each time point there are at least 6 AC animals, 9 HUC animals, 11 
RIS animals, and 13 ALN animals. Proximal Metaphysis Densitometric Properties 
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The values of proximal metaphysis densitometric properties are given in Table 2. 
BMC and vBMD were measured for the total, cortical and cancellous regions of the 
bone. All measures of bone mineral content (BMC) and bone mineral density (vBMD) 
are lower due to HU. Total BMC (Figure 13) for HUC was significantly lower than AC 
(10.3 mg/mm versus 12.8 mg/mm). There was also a significant difference between RIS 
(11.8 mg/mm) and ALN (11.7 mg/mm) versus HUC at the end of the HU period. RIS 
and ALN had a higher value than HUC, suggesting a mitigating effect of drug treatment. 
At the end of recovery these three groups were at level of AC. Total vBMD, in Figure 
14, followed a similar trend but had no significant differences.  
Cancellous BMC in Figure 15 also followed similar pattern to those of total BMC. 
The drug groups are not different from AC at day 56, but were much higher than the 
BMC of HUC. Cancellous vBMD (Figure 16) indicated that ALN and RIS, 236.6 
mg/mm3 and 252.9 mg/mm3 respectively, were significantly higher than HUC, 170.5 
mg/mm3, at the end of HU, and HUC was significantly lower than AC (236.4 mg/mm3). 
This lack of difference between ALN, RIS, and AC suggest that the pre-treatments 
mitigated HU losses. At the end of recovery, the drug pre-treatments still demonstrated a 
positive effect. ALN had a cancellous vBMD of 238.0 mg/mm3 and RIS had a 
cancellous vBMD of 239.5 mg/mm3, while AC had a cancellous vBMD of 197.93 
mg/mm3.  
Cortical BMC (Figure 17) indicated that RIS, HUC, and ALN all had significantly 
lower BMC compared to AC after HU. ALN had a BMC of 8.83 mg/mm; RIS had a 
BMC of 8.85 mg/mm; HUC had a BMC of 8.32 mg/mm; and AC had a BMC of 9.90 
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mg/mm. BMC was gained over recovery to levels that are not statistically different from 
AC. In Figure 18, cortical vBMD had a difference from all other BMC and vBMD 
trends. The drug groups trended towards a gain in vBMD over pre-treatment. and then 
declined for the remainder of the study. For all intents and purposes, these values can be 
considered essentially constant as the largest change is about 3.5%. 
Table 2. Densitometric Properties Measured at the Proximal Tibia Metaphysis. 
 
  Total BMC Total vBMD Cancellous BMC Cancellous vBMD Cortical BMC Cortical vBMD 
Baseline (mg) (mg/cm3) (mg) (mg/cm3) (mg) (mg/cm3) 
AC 13.07 (1.18) 599.7 (27.9) 3.38 (0.84) 259.4 (27.7) 9.69 (0.78) 1037.0 (40.2) 
End of Pre-treatment (Day 28) 
AC 12.59 (0.96) 582.4 (32.9) 2.97 (0.98) 227.5 (34.0) 9.61 (0.65) 1040.1 (44.8) 
ALN 12.29 (1.60) 616.0 (51.0) 2.63 (1.00) 229.0 (59.4) 9.66 (0.99) 1075.6 (39.2) 
RIS 12.41 (0.90) 608.5 (28.8) 2.89 (0.65) 245.6 (43.9) 9.52 (0.45) 1059.1 (22.4) 
End of Hindlimb Unloading (Day 56) 
AC 12.84 (1.23) 609.2 (46.2) 2.94 (1.02) 236.4 (38.4) 9.90 (0.45) 1061.2 (47.4) 
HUC 10.26# (0.82) 553.6 (55.2) 1.94 (0.64) 170.5# (27.5) 8.32# (0.79) 1059.1 (57.7) 
ALN 11.69† (1.17) 590.3 (35.3) 2.86 (0.97) 236.6† (41.2) 8.83# (0.61) 1058.9 (47.3) 
RIS 11.83† (1.31) 604.9 (47.0) 2.98 (0.89) 252.9† (32.9) 8.85# (0.88) 1057.8 (50.7) 
End of Recovery (Day 112) 
AC 12.38 (1.15) 578.5 (26.8) 2.54 (0.97) 197.9 (43.2) 9.84 (0.62) 1070.3 (38.1) 
HUC 11.94 (1.30) 578.38 (37.5) 2.40 (0.97) 192.7 (40.9) 9.54 (0.63) 1061.7 (41.0) 
ALN 12.62 (1.39) 576.9 (38.8) 3.21 (1.03) 238.0 (39.5) 9.41 (0.82) 1043.4 (43.6) 
RIS 12.47 (1.65) 599.3 (30.3) 3.03 (1.04) 239.5† (45.3) 9.44 (0.89) 1059.2 (45.1) 
 
Values presented as Mean and (Standard Deviation) 
† - Indicates significant difference compared to HUC (p < 0.05)  
# - Indicates significant difference compared to AC (p < 0.05) 
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Figure 13. Total Bone Mineral Content for Tibia Metaphysis from Ex Vivo pQCT.  
Gray region represents HU. HUC is significantly lower than AC at day 56. Both 
drug treatments were lower than AC, but have significantly higher values than 
HUC at day 56. At both day 28 and day 112, there are no significant differences in 
the data. Values are presented as mean ± SD. 
 
† - Indicates significant difference compared to HUC (p < 0.05)  
# - Indicates significant difference compared to AC (p < 0.05) 
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Figure 14. Total Bone Mineral Density for Tibia Metaphysis from Ex Vivo pQCT.  
Gray region represents HU. Total BMD was higher for AC compared to HUC, RIS, 
and ALN at day 56. Both RIS and ALN had higher values at day 28 than AC and 
HUC. By day 112, RIS had the highest BMD and the other groups had around the 
same BMD. There was no significance at day 28 or 112. Values are presented as 
mean ± SD.  
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Figure 15. Cancellous Bone Mineral Content for Tibia Metaphysis from Ex Vivo 
pQCT. 
Gray region represents HU. Both drug groups had relatively consistent BMC levels 
throughout the study with ALN finishing with a higher BMC at day 112. The HUC 
group was lower than the others at day 56. At the end of recovery there was not 
much difference between AC and HUC. Values are presented as mean ± SD.  
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Figure 16. Cancellous Bone Mineral Density for Tibia Metaphysis from Ex Vivo 
pQCT. 
Gray region represents HU. Both drug treatments prevented bone loss compared to 
HUC at day 56. The values of ALN and RIS were close to that of AC which was 
shown to be significantly higher from HUC. At day 112, ALN and RIS maintained 
the same level of BMD, while AC and HUC were at the same level, lower than the 
drug treatment groups. RIS was the only drug treatment that showed significance 
at day 112. Values are presented as mean ± SD.  
 
† - Indicates significant difference compared to HUC (p < 0.05)  
# - Indicates significant difference compared to AC (p < 0.05) 
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Figure 17. Cortical Bone Mineral Content for Tibia Metaphysis from Ex Vivo 
pQCT. 
Gray region represents HU. All groups that were subjected to HU were 
significantly lower at day 56. Both drugs had about the same BMC, HUC had the 
lowest BMC. By day 112, ALN, RIS, and HUC had recovered these losses in BMC 
as they no longer showed a significant difference. Values are presented as mean ± 
SD.  
 
# - Indicates significant difference compared to AC (p < 0.05) 
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Figure 18. Cortical Bone Mineral Density for Tibia Metaphysis from Ex Vivo 
pQCT. 
Gray region represents HU. There were no significant changes over time in cortical 
vBMD. The interesting result is that there was very little difference between groups 
at day 56. This is in spite of the significant losses shown in cortical BMC, Figure 23. 
Values are presented as mean ± SD.  
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5.1.1. Proximal Metaphysis Geometric Properties 
The geometric properties as measured at the proximal metaphysis are given in Table 
3. The reported parameters were area of the total, cortical and cancellous regions as well 
as the polar area moment of inertia. The total area of bone (Figure 19) was lower for all 
animals that underwent HU by day 56. HUC had the lowest total area but was not 
significantly lower than the other groups.  
Cortical area (Figure 20) showed a trend that is similar to cortical BMC (Figure 17). 
The cortical area was measured to be significantly lower than AC for ALN, RIS and 
HUC at day 56. Cortical area were 9.38 mm2 for AC, 7.87 mm2 for HUC, 8.36 mm2 for 
ALN, and 8.40 mm2 for RIS. There is little difference between the drug groups at all 
time points.  
Figure 21, endocortical area, did not show any significant differences in cancellous 
area over the duration of the study. Similarly, the same lack of significant differences 
was true for polar moment area of inertia (PAMOI), in Figure 22.  
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Table 3. Geometric Properties Measured at the Proximal Tibia Metaphysis 
 
  Total Bone Area Endocortical Area Cortical Area PAMOI 
Baseline (mm2) (mm2) (mm2) (mm4) 
AC 21.95 (2.8) 12.55 (2.14) 9.40 (0.84) 122.97 (89.38) 
End of Pre-treatment (Day 28)         
AC 21.76 (2.3) 12.49 (2.10) 9.27 (0.58) 98.79 (28.79) 
ALN 20.18 (3.4) 11.15 (2.38) 9.03 (1.12) 83.76 (27.61) 
RIS 20.47 (1.7) 11.46 (1.32) 9.01 (0.48) 82.52 (13.12) 
End of Hindlimb Unloading (Day 56) 
AC 21.35 (3.3) 11.97 (2.68) 9.38 (0.68) 95.79 (31.11) 
HUC 18.79 (2.5) 10.92 (2.23) 7.87# (0.6) 72.74 (18.04) 
ALN 19.96 (2.6) 11.60 (2.22) 8.36# (0.63) 80.76 (20.46) 
RIS 19.79 (3.1) 11.39 (2.53) 8.40# (0.88) 80.59 (24.92) 
End of Recovery (Day 112) 
AC 21.53 (2.2) 12.30 (1.80) 9.22 (0.64) 95.08 (20.66) 
HUC 20.86 (3.0) 11.84 (2.50) 9.02 (0.72) 89.67 (25.29) 
ALN 22.06 (2.8) 13.00 (2.25) 9.05 (0.83) 100.04 (27.55) 
RIS 20.99 (3.3) 12.03 (2.41) 8.96 (1.00) 91.14 (26.28) 
 
 
Values presented as Mean and (Standard Deviation) 
Note: PAMOI – Polar Moment Area of Inertia 
# - Indicates significant difference compared to AC (p < 0.05)  
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Figure 19. Total Bone Area for Tibia Metaphysis from Ex Vivo pQCT.  
Gray region represents HU. There were no significant changes. ALN and RIS had 
higher areas than HUC at day 56. AC had the highest area at day 56; ALN had the 
highest area at day 112. Values are presented as mean ± SD.  
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Figure 20. Cortical Bone Area for Tibia Metaphysis from Ex Vivo pQCT.  
Gray region represents HU. At day 56, HUC, ALN, and RIS all had significantly 
lower areas than AC. By day 112 there were no remaining significant differences 
between treatments. The HUC group faired worst at day 56, while ALN and RIS 
did not show any differences. Values are presented as mean ± SD.   
 
# - Indicates significant difference compared to AC (p < 0.05) 
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Figure 21. Endocortical Area for Tibia Metaphysis from Ex Vivo pQCT.  
Gray region represents HU. This area changed little when looking at each time 
point. There were no significant differences between groups. Values are presented 
as mean ± SD.  
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Figure 22. Polar Area Moment of Inertia for Tibia Metaphysis from Ex Vivo 
pQCT. 
Gray region represents HU. PAMOI remained roughly constant between groups. 
The HUC group was lowest at day 56. Both drugs had around the same values for 
all time points. Values are presented as mean ± SD.  
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5.1.2. Mid-Diaphysis Densitometric Properties 
At the mid-diaphysis of the tibia, no differences were found to be significant at all 
time points for both cortical BMC and cortical vBMD. The numerical results for both 
measures are shown in Table 4. Cortical BMC is plotted in Figure 23 and cortical vBMD 
is plotted in Figure 24. Cancellous measures of densitometry are not considered at this 
location because this is not a region where cancellous bone can be measured. Cancellous 
bone is not part of the structure at the mid diaphysis. There was a slight trend of 
increasing values over time, but again, there were no significant differences.  
5.1.3. Mid-Diaphysis Geometric Properties 
Geometric data from the pQCT scans at the mid-diaphysis included endocortical and 
cortical area, and polar area moment of inertia. Endocortical area is included because it 
indicates how the cavity at the interior of the mid-diaphysis changed during the study. 
The full geometric results are show in Table 5. Figure 25 ‒ Figure 27 report the 
measured values of area for each of the time points. No statistical differences were found 
for any of the mid-diaphysis geometric properties. 
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Table 4. Densitometric Properties of the Tibia Mid-Diaphysis. 
 
  Cortical BMC Cortical vBMD 
Baseline (mg) (mg/cm3) 
AC 8.26 (0.51) 1376.8 (9.18) 
End of Pre-treatment (Day 28)  
AC 8.41 (0.43) 1382.1 (9.52) 
ALN 8.59 (0.58) 1386.1 (15.7) 
RIS 8.62 (0.55) 1384.3 (11.2) 
End of Hindlimb Unloading (Day 56) 
AC 8.55 (0.73) 1398.9 (13.5) 
HUC 8.39 (0.47) 1393.9 (16.2) 
ALN 8.59 (0.71) 1389.9 (25.4) 
RIS 8.79 (0.36) 1377.4 (31.2) 
End of Recovery (Day 112)   
AC 9.04 (0.43) 1406.8 (12.8) 
HUC 9.01 (0.64) 1394.1 (29.3) 
ALN 9.01 (0.65) 1401.9 (9.53) 
RIS 9.17 (0.59) 1401.3 (9.85) 
 
 
Values presented as Mean (Standard Deviation) 
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Figure 23. Cortical Bone Mineral Content for Tibia Diaphysis from Ex Vivo pQCT. 
Gray region represents HU. There were no significant differences at any time point. 
The data shows a general trend of increasing cortical BMC over time. Values are 
presented as mean ± SD. 
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Figure 24. Cortical Bone Mineral Density for Tibia Diaphysis from Ex Vivo pQCT. 
Gray region represents HU. There were no significant differences. There is an 
increasing trend in cortical vBMD over time. Values are presented as mean ± SD. 
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Table 5. Geometric Properties of the Tibia Mid-Diaphysis 
 
  Endocortical Area Cortical Area PAMOI 
Baseline (mm2) (mm2) (mm4) 
AC 2.66 (0.34) 6.00 (0.37) 11.33 (1.47) 
End of Pre-treatment (Day 28) 
AC 2.46 (0.23) 6.09 (0.31) 11.27 (1.16) 
ALN 2.49 (0.38) 6.20 (0.42) 11.70 (1.8) 
RIS 2.43 (0.29) 6.23 (0.42) 11.68 (1.69) 
End of Hindlimb Unloading (Day 56) 
AC 2.56 (0.45) 6.11 (0.54) 11.65 (2.36) 
HUC 2.35 (0.45) 6.01 (0.33) 10.85 (1.55) 
ALN 2.35 (0.48) 6.18 (0.47) 11.53 (1.9) 
RIS 2.40 (0.41) 6.39 (0.37) 12.40 (2.03) 
End of Recovery (Day 112) 
AC 2.68 (0.26) 6.43 (0.30) 12.83 (0.93) 
HUC 2.51 (0.50) 6.47 (0.46) 12.81 (2.26) 
ALN 2.63 (0.32) 6.43 (0.45) 12.66 (1.79) 
RIS 2.63 (0.36) 6.54 (0.41) 13.05 (1.75) 
 
 
Values presented as Mean and (Standard Deviation) 
Note: PAMOI – Polar Moment Area of Inertia  
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Figure 25. Endocortical Area for Tibia Diaphysis from Ex Vivo pQCT.  
Gray region represents HU. There is no significance here. Values are presented as 
mean ± SD. 
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Figure 26. Cortical Bone Area for Tibia Diaphysis from Ex Vivo pQCT.  
Gray region represents HU. The cortical area had no significant differences at any 
time point. Values are presented as mean ± SD. 
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Figure 27. Polar Area Moment of Inertia for Tibia Diaphysis from Ex Vivo pQCT. 
Gray region represents HU. The PAMOI is the highest for RIS at every time point. 
HUC has the lowest value at the end of HU. There were no significant differences at 
any time point. Values are presented as mean ± SD. 
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5.1.4. Strength Indices 
There were only two strength indices from the pQCT data that corresponded with the 
mechanical results and they are shown in Table 6. The first was bone strength index 
(BSI), shown in Figure 28, which corresponds to an estimation of compressive stiffness. 
This value was only considered at the metaphysis as it was the region that was 
mechanical tested under compression with the reduced platen compression test. At the 
end of HU, BSI was the lowest for HUC (5.66 mg2/mm4). This was much lower than the 
value of HUC at the beginning of HU (7.31 mg2/mm4). The BSI for HUC at the end of 
HU was significantly lower than AC. Both RIS and ALN had a significantly higher BSI 
than HUC at the same time point. RIS had a BSI of 7.13 mg2/mm4. ALN had a BSI of 
6.88 mg2/mm4.This combination of statistical significances suggest that both 
bisphosphonate pre-treatments were able to mitigate the effects of HU. There were no 
significant differences between groups at day 112.  
The second strength index, stress-strain index (SSI), corresponds to an estimated 
bending strength (Figure 29). This measure was only considered at the mid-diaphysis as 
it was the only location that was subjected to a bending test, the 3-point bending test. 
There was no significance in SSI at any time point.  
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Table 6. Strength Indices from Tibia pQCT Data. 
 
  BSI SSI 
Baseline (mg2/mm4) (mm3) 
AC 7.80 (0.5) 6.25 (0.61) 
End of Pre-treatment (Day 28) 
AC 7.31 (0.6) 6.14 (0.52) 
ALN 7.53 (1.0) 6.34 (0.70) 
RIS 7.54 (0.7) 6.32 (0.75) 
End of Hindlimb Unloading (Day 56) 
AC 7.78 (0.6) 6.29 (0.93) 
HUC 5.66# (0.7) 6.02 (0.65) 
ALN 6.88† (0.7) 6.22 (0.85) 
RIS 7.13† (0.8) 6.45 (0.66) 
End of Recovery (Day 112) 
AC 7.14 (0.8) 6.74 (0.38) 
HUC 6.88 (0.8) 6.75 (0.93) 
ALN 7.26 (0.9) 6.75 (0.74) 
RIS 7.44 (0.9) 6.90 (0.74) 
 
 
Values presented as Mean and (Standard Deviation) 
† - Indicates significant difference compared to HUC (p < 0.05)  
# - Indicates significant difference compared to AC (p < 0.05) 
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Figure 28. Bone Strength Index for Tibia Metaphysis from Ex Vivo pQCT.  
Gray region represents HU. Day 56 shows a drastic decline in BSI for HUC. ALN 
and RIS have a slight decline that returns to the pre-HU value by the end of 
recovery. AC shows a decrease from day 56 to day 112. HUC does not fully recover 
BSI. Values are presented as mean ± SD.  
 
† - Indicates significant difference compared to HUC (p < 0.05)  
# - Indicates significant difference compared to AC (p < 0.05) 
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Figure 29. Stress-Strain Index for Tibia Diaphysis from Ex Vivo pQCT.  
Gray region represents HU. HUC has the lowest SSI for every time point. The SSI 
for RIS is the highest at each time point. There were no significant differences. 
Values are presented as mean ± SD. 
  
5
5.5
6
6.5
7
7.5
8
d0 d28 d56 d84 d112
SS
I (
m
m
3 )
Stress-Strain Index (Diaphysis)
ALN
AC
HUC
RIS
0
62 
 
  
5.2. Ex Vivo 3-Point Bend Test of the Left Tibia 
Each tibia was subjected to a 3-point bending test. The applied load was located 
roughly at the middle of the bone and meant to correspond with the pQCT scans taken at 
the mid-diaphysis. Two sets of measurements were taken from this mechanical testing 
data. Extrinsic properties were measured directly from the force and displacement 
outputs and represent the mechanical behavior of the tibia at the structural level. Intrinsic 
properties were measured using equations from beam theory (Equation 4 ‒ Equation 6) 
and the measured force and displacement data. The intrinsic properties are estimates of 
the material behavior of the bone. 
5.2.1. Extrinsic Mechanical Properties from 3-Point Bending 
The extrinsic mechanical properties were derived directly from the load-
displacement from the 3-point bend test and it included maximum force, stiffness, post-
yield displacement, and energy to fracture. The values for these measurements are given 
in Table 7. Each of these output variables can be found in Figure 30 ‒ Figure 34. There 
were no statistical differences were not found between groups at each time point.  
5.2.2. Intrinsic Mechanical Properties from 3-Point Bending 
The intrinsic mechanical properties were calculated at all time points for all of the 
collected 3-point bending data were ultimate stress, elastic modulus, and pre-yield 
toughness and they are shown in Table 8. The intrinsic mechanical properties mirrored 
the results from the extrinsic mechanical properties. Each of the intrinsic mechanical 
properties are plotted in Figure 35 ‒ Figure 37. There were no significant differences 
found between groups at any time point for these measurements.   
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Table 7. Extrinsic Mechanical Properties from Tibia 3-Point Bending. 
 
 Maximum Force Stiffness 
Energy to 
Fracture 
Displacement at 
Fracture 
Post-Yield 
Displacement 
Baseline (N) (N/mm) (mJ) (mm) (mm) 
AC 120.8 (16.6) 327.4 (51.8) 59.0 (36.4) 0.71 (0.37) 0.39 (0.35) 
End of Pre-treatment (Day 28) 
ALN 113.8 (20.0) 364.3 (31.4) 47.6 (31.0) 0.58 (0.27) 0.34 (0.26) 
AC 119.0 (19.6) 363.5 (25.6) 54.8 (41.4) 0.62 (0.34) 0.37 (0.33) 
RIS 129.2 (6.93) 373.0 (30.7) 63.7 (32.0) 0.71 (0.30) 0.44 (0.30) 
End of Hindlimb Unloading (Day 56) 
AC 125.1 (21.1) 362.9 (64.6) 46.1 (23.7) 0.56 (0.20) 0.31 (0.21) 
HUC 135.8 (11.3) 385.0 (48.5) 64.1 (17.3) 0.69 (0.16) 0.41 (0.18) 
ALN 132.6 (19.6) 348.7 (69.4) 66.2 (22.2) 0.74 (0.21) 0.47 (0.22) 
RIS 135.5 (15.0) 396.6 (50.0) 61.9 (28.4) 0.66 (0.26) 0.38 (0.25) 
End of Recovery (Day 112) 
AC 121.8 (25.7) 413.6 (23.2) 43.0 (31.7) 0.49 (0.25) 0.25 (0.24) 
HUC 119.3 (22.8) 408.3 (33.6) 32.8 (19.7) 0.41 (0.14) 0.17 (0.13) 
ALN 113.4 (32.5) 401.4 (42.2) 38.4 (38.6) 0.45 (0.29) 0.22 (0.26) 
RIS 134.5 (21.5) 407.3 (43.2) 58.8 (40.4) 0.62 (0.31) 0.36 (0.30) 
 
 
Values presented as Mean and (Standard Deviation) 
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Figure 30. Maximum Force for Tibia in 3-Point Bend Test. 
Gray region represents HU. Max force of all groups peaks at day 56. RIS has the 
highest value at day 56. AC has the lowest value at day 56. ALN has the lowest max 
force at d112. There were no significant differences. Values are presented as mean 
± SD. 
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Figure 31. Stiffness for Tibia in 3-Point Bend Test. 
Gray region represents HU. There were no significant differences. Values are 
presented as mean ± SD. 
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Figure 32. Energy to Fracture for Tibia in 3-Point Bend Test.  
Gray region represents HU. RIS has the highest energy at day 28 and day 112. ALN 
has the highest value at day 56. There were no significant differences. Values are 
presented as mean ± SD. 
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Figure 33. Displacement at Fracture for Tibia in 3-Point Bend Test.  
Gray region represents HU. No significant differences. Values are presented as 
mean ± SD. 
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Figure 34. Post-Yield Displacement for Tibia in 3-Point Bend Test.  
Gray region represents HU. RIS has the highest displacement at day 28 and day 
112. ALN has the highest displacement at day 56. HUC has the lowest displacement 
at day 112 and AC has the lowest at day 56. Values are presented as mean ± SD. 
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Table 8. Intrinsic Mechanical Properties from Tibia 3-Point Bending. 
 
  Ultimate Stress Modulus Pre-Yield Toughness 
Baseline (MPa) (MPa) (mJ/mm3) 
AC 184.1 (30.6) 7.11 (1.28) 2.32 (1.76) 
End of Pre-treatment (Day 28) 
AC 179.1 (25.9) 7.88 (0.57) 1.42 (0.24) 
ALN 173.5 (34.6) 7.69 (1.01) 1.49 (0.38) 
RIS 192.6 (17.7) 7.85 (0.77) 1.72 (0.57) 
End of Hindlimb Unloading (Day 56) 
AC 194.0 (24.3) 7.72 (1.60) 1.52 (0.40) 
HUC 215.8 (21.4) 8.66 (0.57) 1.99 (0.43) 
ALN 204.6 (28.9) 7.37 (1.24) 1.80 (0.72) 
RIS 198.1 (27.9) 7.92 (1.32) 2.06 (0.91) 
End of Recovery (Day 112) 
AC 170.4 (36.2) 7.85 (0.47) 1.50 (0.47) 
HUC 168.7 (33.9) 7.84 (0.91) 1.56 (0.68) 
ALN 159.2 (49.3) 7.77 (0.72) 1.37 (0.55) 
RIS 187.3 (30.1) 7.68 (0.73) 1.72 (0.43) 
 
 
Values presented as Mean and (Standard Deviation) 
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Figure 35. Ultimate Stress for Tibia in 3-Point Bend Test.  
Gray region represents HU. RIS has the highest stress at day 28 and day 112. HUC 
and ALN are higher than RIS at day 56 and ALN has the lowest value at day 112. 
Values are presented as mean ± SD. 
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Figure 36. Modulus for Tibia in 3-Point Bend Test.  
Gray region represents HU. The most prominent feature to this plot is that HUC 
has a larger modulus that the other groups at day 56. At day 28 and day 112, there 
are no large differences between groups. Values are presented as mean ± SD. 
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Figure 37. Pre-Yield Toughness for Tibia in 3-Point Bend Test.  
Gray region represents HU. RIS has the highest pre-yield toughness throughout the 
study. ALN has the lowest values at day 112 and AC has the lowest toughness at 
day 56. HUC outperforms ALN at all time points. Values are presented as mean ± 
SD. 
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5.3. Ex Vivo Reduced Platen Compression Test of the Left Tibia 
The reduced platen compression test was completed using machined specimens and 
platens sized to 70% of the largest circle that could be inscribed into the endocortical 
perimeter. For each time point there were at least 5 AC animals, 8 HUC animals, 12 
ALN animals, and 8 RIS animals. For this test, intrinsic properties were calculated using 
platen area according to the equations described in Section 4.5.3.  
5.3.1. Extrinsic Mechanical Properties from RPC Test 
The extrinsic properties reported from this test were maximum force and stiffness; 
the values for each of these are in Table 9. Maximum force (Figure 38) at day 56 for 
ALN (4.0 N) and RIS (5.6 N) were both significantly higher than HUC (1.6 N). HUC 
was significantly lower than AC (6.0 N). Additionally, RIS was significantly higher than 
ALN, and ALN was significantly lower than AC.  
Stiffness, as shown in Figure 39, did not differ much between groups except for day 
56. At the end of HU, RIS, had a stiffness of 57.6 N/mm, and was significantly higher 
than both ALN (stiffness of 33.7 N/mm) and HUC (stiffness of 17.8 N/mm). HUC was 
also significantly lower than the stiffness of AC, 60.4 N/mm.   
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Table 9. Extrinsic Mechanical Properties from Tibia RPC. 
 
  Max Force Stiffness 
Baseline (N) (N/mm) 
AC 8.15 (7.97) 60.2 (71.9) 
End of Pre-treatment (Day 28)  
AC 4.21 (2.64) 33.6 (20.6) 
ALN 4.68 (4.06) 42.3 (37.4) 
RIS 5.11 (3.47) 40.6 (31.0) 
End of Hindlimb Unloading (Day 56) 
AC 5.98 (3.40) 60.4 (35.5) 
HUC 1.76# (1.25) 17.8# (14.5) 
ALN 4.01†# (4.28) 33.7 (31.0) 
RIS 5.60†* (2.32) 57.6†* (28.4) 
End of Recovery (Day 112)  
AC 2.28 (1.38) 20.4 (13.8) 
HUC 2.42 (2.87) 19.4 (16.2) 
ALN 3.72 (2.77) 36.8 (40.6) 
RIS 2.38 (1.41) 27.1 (14.0) 
 
 
Values presented as Mean and (Standard Deviation) 
† - Indicates significant difference compared to HUC (p < 0.05)  
# - Indicates significant difference compared to AC (p < 0.05) 
* - Indicates significant difference compared to ALN (p < 0.05) 
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Figure 38. Maximum Force for Tibia Metaphysis in RPC Test.  
Gray region represents HU. The maximum force peaked for RIS and AC at day 56. 
RIS and ALN were significantly higher values than HUC at the end of HU. HUC 
had significantly lower values than AC at the same time point. By day 112, there 
were no significant differences between groups. Values are presented as mean ± SD.  
 
† - Indicates significant difference compared to HUC (p < 0.05)  
# - Indicates significant difference compared to AC (p < 0.05) 
* - Indicates significant difference compared to ALN (p < 0.05) 
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Figure 39. Stiffness for Tibia Metaphysis in RPC Test.  
Gray region represents HU. RIS was significantly higher stiffness than HUC and 
ALN. HUC had significantly lower stiffness than AC. Day 112 had no significant 
differences. Values are presented as mean ± SD.  
 
† - Indicates significant difference compared to HUC (p < 0.05)  
# - Indicates significant difference compared to AC (p < 0.05) 
* - Indicates significant difference compared to ALN (p < 0.05) 
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5.3.2. Intrinsic Mechanical Properties from RPC Test 
The intrinsic properties recorded from this test were ultimate stress, modulus and 
strain at yield. These can be found in Table 10. For ultimate stress (Figure 40), RIS and 
ALN were both significantly higher than HUC at day 56, but they were not significantly 
different from each other or AC. AC had the highest ultimate stress of 1.7 MPa at day 56 
followed by RIS at 1.5 MPa. ALN had an ultimate stress of 1.0 MPa and HUC an 
ultimate stress of 0.5 MPa. There were no significant differences at the end of recovery. 
Modulus, in Figure 41, followed similar trends to the measurements of ultimate 
stress. The only significant differences occurred at day 56. At this time point, both drug 
groups had a significantly higher modulus than HUC, 36.2 MPa for ALN and 27.8 MPa 
for RIS versus 9.65 MPa for HUC. HUC was significantly lower than AC (18.2 MPa). 
Day 28 and day 112 did not have any significant differences.  
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Table 10. Intrinsic Mechanical Properties from Tibia RPC. 
 
  Ultimate Stress Modulus Strain at Yield 
Baseline (MPa) (MPa) (mm/mm) 
AC 2.02 (1.76) 28.6 (31.5) 0.03 (0.02) 
End of Pre-treatment (Day 28) 
AC 1.10 (0.72) 17.6 (11.1) 0.05 (0.01) 
ALN 1.35 (1.27) 23.3 (23.06) 0.04 (0.02) 
RIS 1.34 (0.94) 20.7 (15.7) 0.05 (0.02) 
End of Hindlimb Unloading (Day 56) 
AC 1.73 (0.96) 36.2 (28.1) 0.04 (0.01) 
HUC 0.50# (0.30) 9.7# (5.78) 0.03 (0.01) 
ALN 1.04† (0.79) 18.2† (10.7) 0.04 (0.02) 
RIS 1.48† (0.77) 27.8† (15.2) 0.04 (0.02) 
End of Recovery     
AC 0.66 (0.36) 10.9 (6.23) 0.04 (0.02) 
HUC 0.68 (0.69) 10.5 (7.29) 0.03 (0.01) 
ALN 0.98 (0.71) 18.9 (20.4) 0.04 (0.02) 
RIS 0.67 (0.34) 14.3 (6.58) 0.03 (0.01) 
 
 
Values presented as Mean and (Standard Deviation) 
† - Indicates significant difference compared to HUC (p < 0.05)  
# - Indicates significant difference compared to AC (p < 0.05) 
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Figure 40. Ultimate Stress for Tibia Metaphysis in RPC Test.  
Gray region represents HU. Ultimate stress showed that AC had the highest 
ultimate stress, but was not significantly different from the drug pre-treatment 
groups. ALN and RIS were significantly higher than HUC. HUC was significantly 
lower than AC. By the end of recovery there were no more significant differences 
between groups. Values are presented as mean ± SD.  
 
† - Indicates significant difference compared to HUC (p < 0.05)  
# - Indicates significant difference compared to AC (p < 0.05) 
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Figure 41. Modulus for Tibia Metaphysis in RPC Test.  
Gray region represents HU. The AC animals had the highest modulus at day 56. 
RIS and ALN were lower than AC, but only significantly different (higher) than 
HUC. HUC was significantly lower than AC. At the end of recovery, there were no 
more significant differences between groups. Values are presented as mean ± SD.  
 
† - Indicates significant difference compared to HUC (p < 0.05)  
# - Indicates significant difference compared to AC (p < 0.05) 
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6. DISCUSSION 
The overall trend in the data across all variety of measures shows that the two 
bisphosphonates, alendronate and risedronate, were effective in limiting the detrimental 
effects of hindlimb unloading (HU) when administered as a pre-treatment.  
Bisphosphonate treatments are typically administered concurrently with bedrest, 
spaceflight, or HU as a countermeasure to the unloading of actual or simulated 
microgravity. The unique discovery in this study is that it shows they have been effective 
when given prior to the unloading. This study showed, across a variety of metrics, that 
the drugs effectively prevent the levels of bone deterioration that were seen in the 
hindlimb unloading control (HUC) animals. This effect of the pre-treatment is despite 
the fact that the effect of the drugs is somewhat reduced compared to treatment 
concurrent with HU. The following sections will expand upon how these trends were 
apparent or unapparent in each of the measurements made on the tibia.  
6.1. Comparison of pQCT Results 
The pQCT measurements in the metaphysis show the greatest amount of difference 
between the different treatment groups. For the majority of the pQCT results, there were 
no differences at any time point other than the end of HU. At the mid-diaphysis, there 
were no differences shown between groups across any of the time points.  
6.1.1. Densitometric Measurements at the Proximal Tibia Metaphysis 
Densitometric measurements of BMC and vBMD across all compartments (total, 
cancellous, and cortical) at the proximal tibia metaphysis provide insight into how bone 
mineral changed at each time point. Cortical bone had significantly lower BMC for 
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ALN, RIS, and HUC compared to AC at the end of HU on day 56. This suggests that the 
drugs were unable to maintain cortical bone at the same level as AC. Cortical vBMD had 
no significant differences. This measurement is a normalization of cortical BMC by 
cortical volume (area times scan slice thickness) and suggests that changes in area 
caused the significantly lower values of cortical BMC. Unlike the cortical region, the 
cancellous region had significant differences for vBMD only. Cancellous vBMD was 
significantly lower for HUC compared to AC, ALN, and RIS at the end of HU. ALN and 
RIS were not statistically different than AC. This suggests that the drugs were able to 
prevent losses in cancellous vBMD and maintain them at levels similar to control.  
When both the cortical and cancellous regions are considered together in total BMC 
and total vBMD, the only significant differences observed were in the measurement of 
total BMC. The values of total BMC were significantly higher than HUC for both 
bisphosphonates and for AC. There was no significant difference between AC and the 
drug groups. This lack of significance was in spite of the fact that there were significant 
losses in these groups in cortical BMC, a component of total BMC, compared to AC. 
These results suggest that both drugs were effective in preventing losses due to HU for 
total BMC. This highlights an important difference between cortical and total BMC as 
cortical BMC showed the drug treatments were significantly lower than AC at day 56, 
unlike total BMC.  
Considering the cortical and cancellous densitometry measures in conjunction with 
the results from the total metaphysis cross-section, they suggest that the drugs were most 
effective in the cancellous compartment. While there was not a statistically significant 
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effect of HU in cancellous BMC for HUC, the measured values at day 56 for both ALN 
and RIS were almost equivalent to AC. Although cortical BMC loss could not be 
prevented by the drugs, the maintenance of cancellous BMC was able to mitigate the 
reductions in total BMC due to HU. The results from vBMD further support the notion 
that the cancellous compartment experienced the main effect of the bisphosphonate pre-
treatment. 
The data presented here echo the results of other studies that have shown that 
bisphosphonate treated animals were able to totally or partially avoid the bone loss seen 
in HUC. In rats of the same age, receiving a higher dose (30 μg/kg) of alendronate given 
concurrently to 28 days of HU, the drug was observed to have significant beneficial 
effects [42]. In this study, Swift et al. found that HU decreased total vBMD, total BMC 
and cancellous vBMD. On the other hand, the current study showed significantly lower 
values between HUC and AC for only total BMC and cancellous vBMD, but not for 
total vBMD. Nevertheless, the effects of both bisphosphonate pre-treatments on total 
BMC and cancellous vBMD in the current study were essentially the same as the effects 
of a concurrent alendronate treatment as measured by Swift et al. [42]. Both the current 
study and Swift et al. showed that alendronate mitigated the losses due to HU for total 
BMC [42]. These values for the drug treated animals were lower than AC but 
significantly higher than HUC. For cancellous vBMD, both studies showed fully 
protective effects, with the drug treated animals having essentially the same values as 
controls after 28 days of HU. 
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In other disuse models, both risedronate and alendronate have been shown to 
significantly protect against bone loss (BMD) in the tibia metaphysis. Mosekilde et al. 
showed that in 4 month old female rats both alendronate and risedronate were able to 
prevent losses in DXA measurements of aBMD in the proximal tibia metaphysis [43]. 
Unloading was achieved in this model by taping one hindlimb to the abdomen for a 28 
day period of unloading. Untreated animals lost 9.5 % aBMD in the proximal tibia over 
the immobilization period while both bisphosphonates demonstrated positive effects for 
at least the two highest out of the three doses studied [43]. Risedronate was dosed at 0.1, 
0.2 and 1.0 mg/kg and yielded significantly higher aBMD than HUC for the two higher 
doses (6% and 9 %, respectively) [43]. Alendronate was dosed at 0.2, 1.0, and 2.0 mg/kg 
and showed slightly milder beneficial effects, with aBMD significantly higher than HUC 
for the two higher doses (6% and 6.6%, respectively) [43]. In the current study, total 
vBMD for HUC was 9.3% lower than AC at the end of unloading, but not statistically 
significant. However, when considering total BMC and cancellous vBMD, the drug 
treatments were similarly effective. Both alendronate and risedronate protected against 
losses from HU. Further, mean values for RIS for both total BMC and cancellous vBMD 
were slightly higher at the end of HU when compared to ALN pre-treated animals, 
which is also consistent with the study by Mosekilde et al. [43]. Both Mosekilde et al. 
and the current study did not show any major statistical significant differences between 
either of these two drugs.  
Additionally, other studies with alendronate, in concordance with this study, showed 
that treatment to counteract HU helped maintain bone density in the proximal tibia 
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metaphysis across all compartments [13], [14]. These two studies both used rats that 
started at a younger age, but the effect of alendronate is still clear. The concurrent 
treatment showed ALN had a significantly higher tibia aBMD at the end of 28 days of 
HU (25 % greater than HUC) [13]. Apseloff et al. pre-treated animals 2 days before 
unloading [13]. The results showed that ALN had a significantly higher tibia aBMD than 
HUC (45% greater) [14]. These two studies have different designs than the current 
study, so direct comparisons are problematic. The general finding is that alendronate is 
consistently protective against the negative effects of HU. Furthermore, comparing the 
results to those of similar studies [13], [14], [42], [43], emphasizes the noteworthy 
finding of the current study that bisphosphonates, given as a pre-treatment prior to HU, 
still result beneficial effects generally as effective as concurrent administration. 
Previous human spaceflight studies also offer another comparison to the current rat 
model in this study. The use of alendronate, in addition to exercise, was shown to 
improve densitometric measurements at multiple anatomic sites when compared to 
untreated crew members of the International Space Station (ISS) [8]. LeBlanc et al. 
studied 7 ISS crew members who took alendronate during 4-6 months of spaceflight. 
They showed that the alendronate treatment was able to mitigate losses in cortical, 
cancellous and total aBMD and BMC at the femoral neck seen in the non-drug treated 
crew members [8]. These changes are measured over time by comparing pre- and post-
flight in vivo scan measurements. The results for cancellous aBMD are most comparable 
to the cancellous vBMD in the current study, and the effects of the drug treatments are 
similar. That is, the HUC animals at the end of HU had significantly lower cancellous 
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vBMD than both drug treatments suggesting that the drug treatments mitigated losses 
over HU. LeBlanc et al. also showed the most prominent effects in the cancellous 
compartment (of the femoral neck in their case). They report actual increases in 
cancellous vBMD (+6.5%) and cancellous BMC (+20.9%) over the duration of the 
spaceflight mission on the ISS [8]. Leblanc et al. found similar significance to the HU 
results in total BMC as well. The one major difference between the results of the two 
studies is that the astronauts experienced a mitigating effect of alendronate in the cortical 
BMC of the femoral neck, while ALN, RIS, and HUC all lost cortical BMC with no 
differences between these groups in the current study. Overall, however, there are 
considerable similarities in the effects of bisphosphonates on the response of the 
skeleton to mechanical unloading. 
The current study was unable to show any significant differences at the end of 
recovery except for in cancellous vBMD. This difference was could be suggesting a 
prevention of age related decline. The combination of significance in the cancellous 
vBMD and the lack of significant differences elsewhere suggests that the drugs do not 
hinder recovery during return to weight bearing. In fact, they may actually be better off 
during recovery because of this potential prevention of age related decline. While there 
are few studies that examine the effects of recovery, the observed differences at the end 
of recovery in the proximal tibia metaphysis shown in this study are comparable to other 
results [22], [44]. All of these studies showed that there were no differences at the end of 
recovery in any BMC or BMD measurements when comparing hindlimb unloaded 
controls to age matched control animals. Comparable changes during recovery in human 
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models follow the trends in these other rat HU studies. The same effects of recovery 
have been observed in both bed rest [45] and spaceflight reambulation [46]. Both of 
these studies showed an eventual complete recovery that was not statistically different 
from pre-disuse values. 
In a related study observing treatments of alendronate and risedronate on 
ovariectomized rats, the effect of both drugs were shown to persist through a period 
twice as long as the treatment period [38]. This is corroborated by data that showed a 
significantly higher cancellous vBMD for RIS at day 112 compared to AC. With the 
knowledge that the drugs were found to still have an effect on the tibia at day 112, it is 
reasonable to say that they did not show any evidence of a negative effect during the 
recovery period. This finding was contrary to the expectation that differences between 
both bisphosphonates would be evident in the recovery of the animals from HU.  
6.1.2. Comparing the Metaphysis and the Mid-Diaphysis 
 Due to the lack of significance in the mid-diaphysis, the changes in treatment 
between groups did not translate to all parts of the tibia. The effects of both the 
bisphosphonates and HU seem to be site specific and not causing the same effects for 
both of the regions of the tibia. For the metaphysis, it is clear that the bisphosphonates 
are not able to prevent losses in the cortical region, but were able to maintain bone in the 
cancellous region. Cancellous bone has a much higher surface area than cortical bone, 
due to the porous network that makes up cancellous bone. This is why the effect is much 
more pronounced in proximal tibia metaphysis than the mid-diaphysis. The drugs were 
unable to significantly affect the mid-diaphysis cortical BMC because there was a 
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significantly reduced surface area available for binding. This is not a major factor, 
however, because no effects of HU are typically observed at the tibia diaphysis anyway. 
6.1.3. Geometric Measurements at the Proximal Tibia Metaphysis 
For the geometric measurements at the metaphysis, there were significant changes in 
cortical area only. The cortical areas of ALN, RIS, and HUC were significantly lower 
than AC. The measurements of total bone area, endocortical area and PAMOI did not 
show any significant changes at any time point. Since endocortical area was largely 
constant, but larger than the cortical area, significant changes in cortical area are not 
reflected as significant changes in the total area. In other words, because endocortical 
area a much greater proportion of the total cross-section, the total area results do not 
show any significant differences even though cortical area results do show significant 
differences. 
This may be one possible explanation for the reduction in BMC seen in the cortical 
metaphysis and not in the cortical mid-diaphysis. The cortical BMC changes occur in the 
metaphysis because bone is being removed from the cortical region causing a reduction 
in area. BMC is based on the amount of mineral present, and does not normalize for the 
total volume scanned like vBMD. The vBMD measurements do not show any difference 
in the cortical region for both the mid-diaphysis and metaphysis.  
6.2. Comparison of 3-Point Bend Results 
The 3-point bending at the mid-diaphysis did not offer any significant differences in 
the effects of HU or bisphosphonate drug treatments. Also, the 3-point bending stiffness 
and SSI results both had no significance.  
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The lack of an effect of HU in the mid-diaphysis is consistent with the findings of 
other studies. That is, 28 days of hindlimb unloading in adult male rats does not typically 
result in any significant changes in the tibia mid-diaphysis for either extrinsic or intrinsic 
mechanical properties from 3-point bending. The findings of Shirazi et al. found a lack 
of significant differences between HU animals and regular control animals across the 
reported measures of extrinsic and intrinsic properties [22]. In this study, energy to 
fracture, pre-yield toughness, and displacement at fracture were reported in addition to 
the mechanical properties measured by Shirazi et al [22]. These additional mechanical 
properties, included in this study, in the showed no significance. Bloomfield et al. 
reported no differences in measured extrinsic or intrinsic results compared to age 
matched controls at day 56 in similarly aged animals [20]. Post-yield displacement, 
energy to fracture, displacement at fracture, and pre-yield toughness were not reported. 
These results corroborate the findings of Shirazi et al. and the current study [22].  
When comparing the mechanical properties measured for alendronate and 
risedronate to other studies of skeletally mature animals show similar results across 3-
point bending mechanical properties. In a study of ovariectomized baboons, the results 
of femoral 3-point bending did not show significant differences in maximum force or 
stiffness compared to control animals [50]. In a study of ovariectomized female beagles, 
significant differences were not shown in tibia 3-point bending mechanical properties for 
equivalent doses of either risedronate or alendronate compared to control [51]. In a study 
of female ovariectomized rats, the 3-point bending measures of maximum force and 
stiffness again showed no significant effect of alendronate compared to age matched 
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control animals at the same time point [52]. These three studies support the findings of 
this study; neither bisphosphonate was able to significantly improve the performance of 
bone at day 56. The HU procedure significantly reduced bone mineral content of the 
HUC group and the effect of the bisphosphonates counteracted that loss.  
6.3. Comparison of RPC Results 
The RPC test results showed a significant difference between groups at the end of 
HU. Both ultimate stress and modulus support the conclusion that bisphosphonates 
protect cancellous bone against losses in HU. Comparing to previous RPC results, the 
modulus and ultimate stress were almost the same as the baseline animals between the 
current study and that of Shirazi et al [47]. Shirazi et al. showed a significant reduction 
in ultimate stress for HUC versus AC after 28 days of unloading. There were no 
differences in modulus after HU [47]. Unlike Shirazi et al, the current study found 
significantly lower values of both ultimate stress and modulus at the end of HU in HUC 
compared to AC. Additionally, ALN and RIS were able to mitigate the effect of HU at 
day 56 and were both significantly higher than HUC. 
Overall, these results are similar to those of the metaphysis pQCT data. They show 
that the mechanical strength of cancellous bone at day 56 is higher than HUC for both 
drug treated groups, and that mechanical strength was lower due to HU. Table 11 shows 
that the differences between various pQCT and RPC measurements and their relative 
percent differences compared to AC. These results show that the differences in mean 
values were for RPC properties than for densitometric variables. There are no 
differences in the statistically significant differences between these two measurements, 
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but the percent differences in the table suggest that smaller, yet still statistically 
significant changes in densitometric variables may have a much larger impact on 
mechanical properties. A comparison of cancellous vBMD and RPC ultimate stress 
suggests that both the negative effects of HU and the beneficial effects of the drug pre-
treatments could be underestimated by pQCT measurements. 
 
Table 11. Comparison of Percent Differences in Means from AC at the End of 
Hindlimb Unloading for pQCT and RPC Measurements. 
 
 
Comparison 
Total 
BMC 
Cancellous 
vBMD BSI 
RPC Ultimate 
Stress 
RPC 
Modulus 
RIS to AC -7.9% † 7.0% † -8.4% † -14.4% † -23.1% † 
ALN to AC -9.0% † 0.1% † -11.6% † -39.8% † -49.8% † 
HUC to AC -20.1% # -27.9% # -27.2% # -70.9% # -73.3% # 
 
† - Indicates significant difference compared to HUC (p < 0.05)  
# - Indicates significant difference compared to AC (p < 0.05) 
 
 
6.4. Overall Conclusions 
Measurements at the metaphysis showed that the drugs were able to counteract the 
effects of HU by maintaining bone at levels of age-matched control (AC). This was 
shown significantly in total BMC and cancellous vBMD. Cortical BMC was unable to 
be maintained at levels of AC; however, the changes in cancellous bone were enough to 
counteract the changes in cortical bone over HU. This prevented significant losses in 
total BMC compared to AC. Over recovery, cortical bone was recovered to nearly the 
same values as AC. The drugs did not hinder the ability of bone to recover, and were 
able to combat the effect of age related decline in HUC and AC over recovery. The mid-
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diaphysis did not show any significant change in BMC or vBMD, suggesting that the 
changes in BMC and vBMD were limited to the metaphysis. 
Geometric measurements of the metaphysis showed decreases over HU and 
increases over recovery to correspond with the densitometric results. The significant 
decrease in cortical area, in conjunction with the significant decrease in cortical BMC 
(both compared to AC), means that HU caused bone to be removed from the cortical 
region. The drugs were unable to significantly alter this effect of HU. The mid-diaphysis 
showed an increase in area and moment of inertia across the course of the study. This 
was in line with age related change and was not influenced significantly by either the 
bisphosphonates or HU.  
Mechanical strength of the mid-diaphysis was evaluated using a 3-point bend test. 
No significant differences were found in the bending results. In spite of this, it seems 
that a difference in the energy to fracture may exist between the drugs. There is research 
that suggests that alendronate may increase the brittleness of bone. The head-to-head 
comparison of energy to fracture for risedronate and alendronate at day 112 suggests that 
this might be slowly occurring. Additionally, the modulus shows a large rise for HUC at 
the end of HU. This was caused by a decrease in cross-sectional moment of inertia. The 
decrease was not significant for HUC, but this decrease was larger than the decrease in 
the drug groups. That kept the modulus closer to the value of AC. A comparison of the 
3-point bending results to an estimated bending strength index from pQCT data did not 
show much similarity. This was because the mechanical testing results and the pQCT did 
not follow the same trends.  
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7. LIMITATIONS 
The rat hindlimb unloaded model has various limitations. The most obvious of these 
is that rats are quadrupeds while humans are not. Rat bone also lacks the same 
intracortial bone structure as humans. With this study in particular, there were other 
imperfections worth noting. Some of the alendronate animals did not receive the correct 
dosing; it was lower than was listed in the method. This did not seem to affect the 
results. There were no explicit significant differences observed between the drugs as this 
was supported by the findings in other published studies. There were also concerns about 
differences in cohort size that may have caused additionally variability. One cohort was 
much smaller than the other two. Again, the design of the study called for multiple 
animals at each time point from each cohort so this distribution was still done randomly.  
For ex vivo testing, there are limitations to the RPC test. There are concerns when 
placing the bone specimen on the platens so only the cancellous bone experiences direct 
contact. Additionally, the largest assumption in the test is that the cancellous bone is 
homogenously distributed throughout the entire cross-section. Unfortunately, this is not 
always the case. The test was completed with as many bones as possible, but some were 
omitted because there were not enough trabeculae to constitute even an imperfect 
mechanical test. That is, the central region of the specimen was mostly devoid of 
cancellous bone. This is why the mechanical properties measured are estimates as they 
were subjected to local variations in structure. The analysis was done carefully and 
systematically to ensure that the results were as valid as possible, but it is impossible to 
avoid some level of variability or imperfection. 
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8. FUTURE WORK 
This study is a part of a larger experiment that compares the effect of these two anti-
catabolic (bisphosphonate) pre-treatments with two anabolic pre-treatments. The 
anabolic treatments utilize an anti-sclerostin antibody and a jumping resistance exercise 
meant to mimic strength training. The resulting comparison will shed light on how 
different methods of pre-treatment compare to one another.  
For the study of the bisphosphonate pre-treatment focused on in this thesis, 
forthcoming data includes histology of the tibia at various locations and a full battery of 
tests for the femur. The femur data will include pQCT scans of the femoral neck, mid-
diaphysis and distal metaphysis. RPC testing of the distal metaphysis, 3-point bending 
and femoral neck testing will all additionally be completed. These measures will also 
assess how the effects of the bisphosphonate treatment will be extend beyond the left 
tibia to other bones in the body.  
The left tibia metaphysis, included in this thesis, will also undergo µCT to analyze 
the changes in microarchitecture in the cancellous bone. To better understand some of 
the effects of the bisphosphonates, it could beneficial to complete a future study that 
extends the recovery time of the animals in HU. This modification may be able to better 
understand how differences in binding affinity affect recovery. The period of recovery 
used in this study is enough to capture the changes that occur directly after spaceflight, 
but bone is constantly changing. There could be effects that occur slowly and appear 
beyond the two month recovery investigated in this study.  
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9. CONCLUSIONS 
This study sought to determine if a bisphosphonate treatment could effectively 
combat the bone loss of hindlimb unloading (HU) when given as a treatment prior to 
unloading rather than concurrently. HU is an effective rat model of human spaceflight 
and was used to understand how the changes in rat bone might reflect changes in human 
bone in microgravity. The aim of this type of study is to better understand the 
countermeasures for treating patients in space and those on earth with conditions that 
cause detrimental bone loss.  
More specifically, this study examined the effects of two different bisphosphonate 
pre-treatments administered prior to a period of HU. The pre-treatment and bout of HU 
were both 28 day long period that were followed by 56 days of recovery, a return to 
normal ambulation. Two bisphosphonates were used in this study to understand how 
differences in binding affinity might affect the effectiveness of treatment. Alendronate, a 
high affinity drug, and risedronate, a lower affinity drug, were the two bisphosphonates 
chosen for this study. The effects of HU were assessed with pQCT scans of the tibia 
metaphysis and mid-diaphysis. Measurements of mechanical strength were also made at 
each location.  
The results from this study are not a direct assessment of how human bone would 
behave under the same situations, but they offer a prediction of what could be expected. 
The tibia metaphysis is selected as a region of interest because the composition of the 
site is comparable to the composition of the human femoral neck. By making this 
comparison, the results of this study suggest that, at the very least, the use of a 
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bisphosphonate pre-treatment would reduce fracture risk upon return from space, and 
would also not hinder the recovery of bone post-spaceflight. It is also reasonable to 
assume that the bisphosphonate chosen will still be able to combat age related bone loss 
over the recovery period. The results also show that the binding affinity of the drug will 
not significantly change how well the drug works to counter HU induced bone loss. 
There was not a noticeable effect of changing the resorption activity of the bone that 
caused a change the brittleness of the bone.  
Broadly speaking, the results of this study show that both bisphosphonates were 
effective countermeasures even though they were given before and not during HU. The 
beneficial effects of the pre-treatments were concentrated in the cancellous compartment 
of the proximal tibia metaphysis. This was found in both densitometric variables and 
mechanical properties. No beneficial effects were observed for the tibia mid-diaphysis; 
however, no detrimental effects of HU were observed at this location in this study and 
other rat studies. In addition, the results from this study showed that neither 
bisphosphonate pre-treatment had a negative effect on the 56 days of reambulation 
recovery that followed HU. Consequently, this study suggests a pre-treatment protocol 
might be effective for bisphosphonates used as countermeasures in human space flight 
scenarios. Finally, no significant differences in relative effectiveness were observed in 
this study between alendronate and risedronate. 
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APPENDIX A. STATISTICAL ANALYSIS 
Table A1. Statistical Analysis of Metaphysis pQCT at the End of Pre-Treatment 
(Day 28). 
Parameter Statistical Test Post Hoc Comparison P-Value
Total BMC ANOVA N/A Overall 0.865 
Total vBMD ANOVA N/A Overall 0.169 
Cancellous BMC ANOVA N/A Overall 0.616 
Cancellous vBMD ANOVA N/A Overall 0.594 
Cortical BMC ANOVA N/A Overall 0.869 
Cortical vBMD Kruskal-Wallis N/A Overall 0.13 
Total Area ANOVA N/A Overall 0.381 
Endocortical Area Kruskal-Wallis N/A Overall 0.39 
Cortical Area ANOVA N/A Overall 0.583 
PAMOI Kruskal-Wallis N/A Overall 0.33 
BSI ANOVA N/A Overall 0.785 
Table A2. Statistical Analysis of Metaphysis pQCT at the End of Hindlimb 
Unloading (Day 56). 
Parameter Statistical Test Post Hoc Comparison P-Value
Total BMC ANOVA Tukey Overall 0.0012 
C-A 0.198 
H-A 0.034 
R-A 0.99 
H-C 0.001 
R-C 0.327 
R-H 0.022 
Total vBMD ANOVA N/A Overall 0.063 
Cancellous BMC ANOVA N/A Overall 0.0523 
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Parameter Statistical Test Post Hoc Comparison P-Value
Cancellous vBMD ANOVA Tukey Overall 0.0000725 
C-A 0.999 
H-A 0.001 
R-A 0.684 
H-C 0.007 
R-C 0.799 
R-H 0.0000604 
Cortical BMC ANOVA Tukey Overall 0.002 
C-A 0.023 
H-A 0.381 
R-A 0.999 
H-C 0.001 
R-C 0.033 
R-H 0.374 
Cortical vBMD ANOVA N/A Overall 0.999 
Total Area ANOVA N/A Overall 0.409 
Endocortical 
Area ANOVA N/A Overall 0.852 
Cortical Area ANOVA Tukey Overall 0.004 
C-A 0.033 
H-A 0.393 
R-A 0.999 
H-C 0.002 
R-C 0.05 
R-H 0.363 
PAMOI Kruskal-Wallis N/A Overall 0.064 
BSI ANOVA Tukey Overall 0.0000198 
C-A 0.0779 
H-A 0.003 
R-A 0.836 
H-C 0.0000212 
R-C 0.313 
R-H 0.000461 
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Table A2. Continued
Table A3. Statistical Analysis of Metaphysis pQCT at the End of Recovery (Day 
112). 
Parameter Statistical Test Post Hoc Comparison P-Value
Total BMC ANOVA N/A Overall 0.708 
Total vBMD ANOVA N/A Overall 0.23 
Cancellous BMC ANOVA N/A Overall 0.187 
Cancellous vBMD ANOVA Tukey Overall 0.012 
C-A 0.159 
H-A 0.061 
R-A 0.999 
H-C 0.994 
R-C 0.118 
R-H 0.04 
Cortical BMC ANOVA N/A Overall 0.624 
Cortical vBMD ANOVA N/A Overall 0.51 
Total Area ANOVA N/A Overall 0.712 
Endocortical 
Area ANOVA N/A Overall 0.587 
Cortical Area ANOVA N/A Overall 0.911 
BSI ANOVA N/A Overall 0.923 
PAMOI ANOVA N/A Overall 0.734 
Table A4. Statistical Analysis of Mid-Diaphysis pQCT at the End of Pre-Treatment 
(Day 28). 
Parameter Statistical Test Post Hoc Comparison P-Value
Cortical BMC ANOVA N/A Overall 0.671 
Cortical vBMD ANOVA N/A Overall 0.78 
Endocortical 
Area ANOVA N/A Overall 0.722 
Cortical Area ANOVA N/A Overall 0.583 
PAMOI Kurskal-Wallis N/A Overall 0.814 
SSI ANOVA N/A Overall 0.77 
Total Area ANOVA N/A Overall 0.863 
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Table A5. Statistical Analysis of Mid-Diaphysis pQCT at the End of Hindlimb 
Unloading (Day 56). 
 
Parameter Statistical Test Post Hoc Comparison P-Value 
Cortical BMC ANOVA N/A Overall 0.49 
Cortical vBMD Kruskal-Wallis N/A Overall 0.3 
Endocortical Area ANOVA N/A Overall 0.795 
Cortical Area ANOVA N/A Overall 0.264 
PAMOI ANOVA N/A Overall 0.372 
SSI ANOVA N/A Overall 0.678 
Total Area ANOVA N/A Overall 0.643 
 
Table A6. Statistical Analysis of Mid-Diaphysis pQCT at the End of Recovery (Day 
112). 
 
Parameter Statistical Test Post Hoc Comparison P-Value 
Cortical BMC ANOVA N/A Overall 0.863 
Cortical vBMD Kruskal-Wallis N/A Overall 0.68 
Endocortical Area ANOVA N/A Overall 0.77 
Cortical Area ANOVA N/A Overall 0.264 
PAMOI ANOVA N/A Overall 0.945 
SSI ANOVA N/A Overall 0.932 
Total Area ANOVA N/A Overall 0.89 
 
Table A7. Statistical Analysis of 3-Point Bending at the End of Pre-Treatment (Day 
28). 
 
Parameter Statistical Test Post Hoc Comparison P-Value 
Maximum Force ANOVA N/A Overall 0.999 
Stiffness ANOVA N/A Overall 0.695 
Energy to Fracture Kruskal-Wallis N/A Overall 0.42 
Displacement at Fracture Kruskal-Wallis N/A Overall 0.51 
Post-Yield Displacement Kruskal-Wallis N/A Overall 0.61 
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Parameter Statistical Test Post Hoc Comparison P-Value
Ultimate Stress Kruskal-Wallis N/A Overall 0.167 
Modulus ANOVA N/A Overall 0.834 
Pre-Yield Toughness Kruskal-Wallis N/A Overall 0.257 
Table A8. Statistical Analysis of 3-Point Bending at the End of Hindlimb Unloading 
(Day 56). 
Parameter Statistical Test Post Hoc Comparison P-Value
Maximum Force ANOVA N/A Overall 0.627 
Stiffness Kruskal-Wallis N/A Overall 0.36 
Energy to Fracture ANOVA N/A Overall 0.364 
Displacement at Fracture ANOVA N/A Overall 0.393 
Post-Yield Displacement ANOVA N/A Overall 0.528 
Ultimate Stress ANOVA N/A Overall 0.378 
Modulus ANOVA N/A Overall 0.12 
Pre-Yield Toughness ANOVA N/A Overall 0.445 
Table A9. Statistical Analysis of 3-Point Bending at the End of Recovery (Day 112). 
Parameter Statistical Test Post Hoc Comparison P-Value
Maximum Force ANOVA N/A Overall 0.178 
Stiffness ANOVA N/A Overall 0.908 
Energy to Fracture Kruskal-Wallis N/A Overall 0.18 
Displacement at 
Fracture Kruskal-Wallis N/A Overall 0.23 
Post-Yield Displacement Kruskal-Wallis N/A Overall 0.46 
Ultimate Stress ANOVA N/A Overall 0.262 
Modulus ANOVA N/A Overall 0.93 
Pre-Yield Toughness ANOVA N/A Overall 0.337 
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Table A10. Statistical Analysis of RPC Test at the End of Pre-Treatment (Day 28). 
 
Parameter Statistical Test Post Hoc Comparison P-Value 
Maximum Force Kruskal-Wallis N/A Overall 0.81 
Stiffness Kruskal-Wallis N/A Overall 0.88 
Ultimate Stress Kruskal-Wallis N/A Overall 0.84 
Modulus Kruskal-Wallis N/A Overall 0.93 
Strain at Yield ANOVA N/A Overall 0.829 
 
Table A11. Statistical Analysis of RPC Test at the End of Hindlimb Unloading (Day 
56). 
 
Parameter Statistical Test Post Hoc Comparison P-Value 
Maximum Force Kruskal-Wallis Dunn's Test Overall 0.01 
      C-A 0.066 
      H-A 0.0693 
      R-A 0.04 
      H-C 0.005 
      R-C 0.497 
      R-H 0.002 
Stiffness Kruskal-Wallis Dunn's Test Overall 0.01 
      C-A 0.056 
      H-A 0.0922 
      R-A 0.0251 
      H-C 0.006 
      R-C 0.469 
      R-H 0.001 
Ultimate Stress Kruskal-Wallis Dunn's Test Overall 0.02 
      C-A 0.1 
      H-A 0.0417 
      R-A 0.1086 
      H-C 0.005 
      R-C 0.417 
     R-H 0.004 
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Parameter Statistical Test Post Hoc Comparison P-Value
Modulus Kruskal-Wallis Dunn's Test Overall 0.03 
C-A 0.111 
H-A 0.051 
R-A 0.106 
H-C 0.008 
R-C 0.444 
R-H 0.004 
Strain at Yield ANOVA N/A Overall 0.615 
Table A12. Statistical Analysis of RPC Test at the End of Recovery (Day 112). 
Parameter Statistical Test Post Hoc Comparison P-Value
Maximum Force Kruskal-Wallis N/A Overall 0.36 
Stiffness Kruskal-Wallis N/A Overall 0.44 
Ultimate Stress Kruskal-Wallis N/A Overall 0.4 
Modulus Kruskal-Wallis N/A Overall 0.42 
Strain at Yield Kruskal-Wallis N/A Overall 0.1 
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APPENDIX B. ADDITIONAL FIGURES 
Figure B1. Calculated Cortical Thickness for Tibia Metaphysis from Ex Vivo 
pQCT.  
Gray region represents HU. The HUC group had a significantly lower thickness 
compared to AC at day 56. ALN and RIS were both lower than AC, but not 
significantly. Cortical thickness was recovered by day 112. Values are presented as 
mean ± SD.  
# - Indicates significant difference compared to AC (p < 0.05) 
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Figure B2. Calculated Cortical Thickness for Tibia Diaphysis from Ex Vivo pQCT. 
Gray region represents HU. There were no significant differences for this 
measurement. Values are presented as mean ± SD. 
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Figure B3. Total Bone Area for Tibia Diaphysis from Ex Vivo pQCT. Gray region 
represents HU. There were no significant differences for this measurement. Values 
are presented as mean ± SD. 
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Figure B4. Strain at Yield for Tibia Metaphysis in RPC Test.  
Gray region represents HU. Strain was not significantly different at any time point. 
Values are presented as mean ± SD.  
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